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Abstract 
 
 
In the last few years, the prevalence of legal party pills in New Zealand has risen 
dramatically. These pills contain new piperazine designer drugs, two of the more 
common being 1-benzylpiperazine (BZP) and m-trifluoromethylphenylpiperazine 
(TFMPP). This thesis describes an optimised LC-MS/MS method for the 
detection of BZP and TFMPP in whole blood, using an automated solid phase 
extraction (SPE) for sample clean-up. The method was validated on three different 
days using five replicate samples each day. The standard curve was linear from 7 
– 7000 ng/mL for BZP and 10 – 10,000 ng/mL for TFMPP, with coefficients of 
variation (CV) below 10%, and accuracy greater than 90% for both drugs. The 
method was used to quantitate samples provided by the Medical Research 
Institute of New Zealand. Blood levels were used to show concentrations in the 
blood over time, and relate these to performance of subjects on a driving 
simulator. The study was stopped after 41% of the participants who received BZP 
and TFMPP had adverse reactions to the pills, including vomiting and migraines. 
 
The LC-MS/MS method was also used to detect and quantitate methamphetamine, 
amphetamine, methylenedioxymethamphetamine, methylenedioxyamphetamine, 
morphine, codeine and 6-monoacetylmorphine in hair. The drugs were extracted 
from 20 mg of hair using hydrochloric acid in a water bath overnight, then 
purified using SPE. Validation on three days with five replicate samples gave 
coefficients of variation (CV) below 12% and acceptable accuracy for all drugs. 
The method was tested on three samples, previously reported by Environmental 
Science and Research (ESR) using gas chromatography mass spectrometry (GC-
MS) giving results in good agreement. 
 
This thesis describes a sensitive, accurate, reproducible LC-MS/MS method easily 
adapted to analyse drugs of abuse in different biological matrices. It demonstrates 
the versatility of LC-MS/MS and its applications in forensic work. 
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Chapter 1: Introduction/Literature Review 
 
1.1. Introduction 
 
Recently, piperazine analogues, a new class of designer drugs, have caught 
the attention of the public, authorities and media, with many questions being 
raised in regard to both their safety and legal status. 1-Benzyl-piperazine 
(BZP) and m-trifluoromethylphenyl-piperazine (TFMPP) are two of the more 
common drugs in this class. With comparisons being made to amphetamine 
and ecstasy (methylenedioxymethamphetamine, MDMA), they have been 
classed as stimulants, reported and advertised to give feelings of euphoria, 
alertness, and a desire to socialise.1 Side effects include a ‘hangover’ (similar 
to that of alcohol), dry mouth and urine retention. The legal status of these 
drugs varies throughout the world and little scientific research on them exists. 
Of what research is available, studies have been conducted on their detection, 
metabolism and neuropharmacology. Due to the legal status of these designer 
drugs in New Zealand, there is plenty of opportunity for study, and the current 
interest they have generated makes the prospect for further study in this field 
exciting and unique.  
 
The detection of these, and other recreational drugs, is important in workplace 
and roadside drug testing, forensic casework and court disputes, for example, 
child custody cases. It is essential to have a method that is simple, robust, 
accurate and reproducible. Traditionally, gas chromatography mass 
spectrometry (GC-MS) is the method of choice for the analyses mentioned 
above and it has a long history of use in the forensic field. GC-MS however, 
requires time-consuming sample preparation or is otherwise limited to volatile 
compounds.2 Liquid chromatography tandem mass spectrometry (LC-
MS/MS) allows the detection and quantitation of many different drugs in 
biological matrices and often requires less sample preparation. According to 
the review by Maurer3 LC-MS/MS has the potential to become the ‘golden 
standard’ for forensic and clinical analysis. 
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This thesis describes an optimised LC-MS/MS method, with solid phase 
extraction, developed for the detection of BZP and TFMPP in whole blood. 
The method has been used to quantitate levels of the drugs in human blood 
samples, taken during research to determine their effects on human driving 
performance. The results from this project will give an idea of the typical 
levels that can be found in users, and provide some insight into the effects that 
these drugs have on humans.  
 
It also examines the use of the above LC-MS/MS method for the analysis of 
these and other commonly abused, recreational drugs in hair. This includes 
drugs such as the amphetamines (methamphetamine (MA), 
methylenedioxymethamphetamine (MDMA)) and the opiates (morphine and 
codeine). Hair testing is becoming a common type of analysis, especially in 
workplace drug testing, drug facilitated sexual assaults and child custody 
disputes. Although hair cannot determine the exact time of exposure, or level 
of impairment, it does offer long-term exposure information not offered by 
other biological specimens such as blood and urine.  
 
1.1.1. Biological Matrix 
 
There are many different forms of samples that can be collected for use in 
drug analysis. These include blood (and its components e.g. plasma, serum), 
urine, oral fluid (saliva), sebum, hair, nails, and skin.  
 
The use of alternative specimens such as hair and nails can be of assistance in 
determining drug use patterns. Examples of uses of alternative specimens are: 
workplace drug testing (hair, sweat, oral fluid), criminal investigations (hair, 
sweat, oral fluid) child custody disputes and divorce cases (hair), and roadside 
testing for drug-impaired drivers (oral fluid).4 The use of hair, nails and oral 
fluid for drug testing is becoming more popular due to its non-invasive 
manner.  
 
Figure 1-1 shows the various biological specimens and the time period in 
which they are useful for the detection of drugs. Blood and oral fluid are 
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useful for immediate detection, and can give an indication of levels of 
impairment in a user. Drugs can be detected in urine (depending on the drug) 
for days. Hair and nails are proving valuable as they can give a history of a 
person’s drug use, but cannot give information of the level of impairment, or 
the precise time of ingestion. 
Figure 1-1: Timeline of Detection of Drugs in Biological Specimens 
 
1.1.1.1. Blood and Urine 
 
Urine is the most widely used biological sample for toxicological analysis. 
Urine demonstrates use of a drug but gives little or no idea of when the drug 
was taken and the magnitude of any pharmacological effect, and therefore 
cannot be used to determine the level of impairment. Urine analysis can also 
be lengthy as there is often a need to identify metabolites due to 
transformation of the drug during metabolism. It is possible to detect 
drugs/metabolites in urine from hours until days (Figure 1-1). 
 
Blood has many advantages as a biological matrix as it can provide 
information about distribution, metabolism, and pharmacokinetics and can be 
used to measure levels almost immediately after administration.5 Plasma is 
often the most common choice for blood analysis, although in autopsy cases 
plasma often cannot be obtained, so whole blood is used. With major 
advances in sample preparation, chromatography, and detectors, the use of 
whole blood as a matrix for quantification and identification has become 
widespread.5 
 
HOURS 
DAYS 
WEEKS 
MONTHS 
Blood 
Hair 
Nails 
Urine 
Saliva 
YEARS 
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1.1.1.2. Hair 
 
The earliest testing of hair for toxins began with heavy metals in the 1950’s 
and escalated in the late 1970s. It is proving valuable in toxicological 
analysis, as it can give an idea of a person’s drug history (months to years, see 
Figure 1-1) and is also non-invasive. Unfortunately it cannot determine the 
level of impairment and can only give an estimate to the time of exposure. It 
is particularly useful in cases where a urine or blood sample was not taken 
soon enough.6 
 
The methods of incorporation of drugs in hair are still a bit unclear. The most 
simple explanation is by way of passive transfer from the blood into the hair 
follicle during formation. However, the multi-compartmental model 
(demonstrated by Henderson7) seems to be the most widely accepted. Here 
the hair is transferred by multiple mechanisms.7,8 
 
Passive Transfer: Occurs via passive diffusion from bloodstream into 
growing hair cells at the base of the follicle. The drug is retained in the 
interior of the hair (medulla), during keratogenesis (formation of 
keratin, hardening of hair). Hair grows approximately 1 cm every 28 
days,8 so roughly, drugs deposited into the hair will be found 
approximately 1 cm from the scalp, one month after the drug was taken. 
Sweat and Sebum: Drugs are transferred into the hair after formation through 
sweat and sebum. Drugs have been found in sweat in higher 
concentrations than found in the blood, so this offers an explanation to 
the higher concentrations sometimes found in the hair.7 
External Environment: Drugs are passed into the hair from the environment. 
This could be through the air, water or hair treatments (dying, perming 
etc.). Drugs such as amphetamine, cannabis, heroin and cocaine are 
often smoked and hence transferred into the hair. 
Intradermal Transfer: Very lipid-soluble drugs such as tetrahydrocannibinol 
(THC, cannabis) are deposited into skin layers and transferred to hair. 
Melanin: Drugs could possibly bind to melanin-related sites in the skin, which 
could result in drug uptake in the hair. 
- 5 - 
 
For analysis using hair, decontamination of the surface of the hair is a vital 
step. It is important to clear the hair of drugs deposited via air or hair 
treatments as mentioned in the multi-compartmental model above. The 
reviews by Pragst et al., Musshoff et al., and Boumba et al. give 
comprehensive overviews of the methods of drug administration of hair 
mentioned above, as well as the structure of hair and methods of drug 
detection.8,9,10 
 
1.1.2. Solid Phase Extraction 
 
Biological samples such as blood, urine and serum are extremely complex. 
Injecting them directly onto expensive and sensitive equipment such as LC 
and GC columns is not a very advisable move. By using an effective method 
such as solid phase extraction (SPE) to clean-up samples, the life of the 
instrument is prolonged, and downtime (for source cleaning) of equipment is 
decreased.11 
 
Liquid-liquid extraction (LLE) is a direct method used to extract compounds 
of interest from complex biological matrices by transferring it from one liquid 
(solvent) to another. It requires two immiscible solvents, often one is aqueous 
and the other organic and depends on the difference in solubility of the 
compound in the different solvents. LLE is frequently used as an efficient 
separation technique, however solid phase extraction is becoming increasingly 
popular. Solid phase extraction (SPE) is an indirect chromatography method 
used to separate an analyte from a liquid, using a solid phase. The analyte/s 
are adsorbed onto the column, and then eluted using a solvent, often one 
which can easily be evaporated or can be used directly for analysis by liquid 
chromatography. 
 
SPE tends to have several advantages over LLE. SPE can easily be automated 
which generally gives better results, has greater reproducibility, a higher 
recovery, saves time by increased throughput and reduces errors. SPE uses 
less solvent and the time analysts spend exposed to organic solvents is 
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decreased. The general process for the SPE, used for sample clean-up is 
pictured in Figure 1-2. First the column is conditioned to prepare it for the 
sample, and then the sample is loaded. The column is washed (to remove 
unwanted analytes not retained by the sorbent), dried and the analytes of 
interest eluted. 
 
The extraction of drugs from hair samples is more complex than from whole 
blood. As drugs and other contaminants can get on to the surface of the hair, a 
decontamination step is required. This usually involves soaking the hair in a 
solvent overnight to remove dirt, externally deposited drugs and other 
contaminants. Once removed, the hair sample can be transferred into solvent 
for the extraction of the drugs from within the sample. The most common 
methods are via chemical hydrolysis, enzymatic digestion or solvent 
extraction. In this study, drugs are extracted from the hair using acid. After 
extraction of the drugs from the hair, the samples still remain fairly dirty, 
therefore SPE is used to clean up the samples. 
- 7 - 
 
Figure 1-2: Diagram Of Solid Phase Extraction Process 
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1.1.3. Liquid Chromatography – Mass Spectrometry 
 
Liquid chromatography (LC) and Gas Chromatography (GC) are 
chromatographic analytical techniques used to separate particular analytes in 
solution. They both consist of a mobile phase and a stationary phase, which 
adsorbs and desorbs the analyte of interest. However, in LC the mobile phase 
is a liquid (normally a mixture of aqueous buffer and organic solvent) and the 
stationary phase usually consists of surface modified silica or polymer 
particles. With GC, the mobile phase is an inert carrier gas and the stationary 
phase can be either an inert porous solid or a solid support coated with a non-
volatile liquid.  
 
Traditionally GC-MS is the method of choice for toxicological analysis, 
however with LC-MS being so diverse it is proving to be a very powerful tool 
in many aspects of drug analysis.12 Recent reviews have shown LC-MS to be 
very significant in pharmaceutical research and clinical and forensic 
toxicology. It has proved especially valuable for the detection and 
quantification of more polar, thermally labile, or low-dosed drugs in blood 
plasma,3 mainly as they do not require derivatisation. It is highly sensitive and 
selective.  
 
The LC column used in this thesis is a strong cation-exchange (SCX) column. 
Ion chromatography separates analytes on the basis of charged particles in 
solution. The stationary phase consists of a polymer that carries a charge (in 
the case of cation-exchange this will be negative). Freely moving counter ions 
pair with the polymer in order to neutralise the charged particles. When the 
solution is introduced, the analytes of interest replace the counter ions and are 
retained by the column. The mobile phase elutes the analytes by providing 
competition for binding sites on the polymer. Cation-exchange can be 
represented by the following equation:13 
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M-C+  +  A+   ! M-A+  +  C+ 
 
(Where M- is the negatively charged stationary phase, C+ is the counterion and A+ is 
the analyte of interest) 
 
 
Mass spectrometry measures and identifies molecules by measuring the mass 
to charge ratio (m/z) of ions. It can be used to quantify and determine chemical 
and structural information about atoms and molecules. An important part of 
the technique is the distinctive fragmentation patterns produced by collisions 
(with gas), which provide significant structural information that helps to 
identify components of the molecule.  
 
In this study, samples will be analysed by LC-MS/MS, using a triple 
quadrupole mass spectrometer. This consists of three quadrupoles arranged 
sequentially, two of which are mass analysing and the third of which is used 
as a collision cell. A quadrupole is made up of four parallel electrodes/poles 
which have DC (direct current) and RF (radio frequency) potentials applied. 
The poles oscillate and attract and repel ions. Only ions with a stable 
trajectory pass through, and unwanted ions hit the poles and lose charge. 
During application, the RF is held constant, and the RF and DC voltages are 
scanned (ratio of RF: DC remains the same). Whether or not an ion has a 
stable motion depends upon the DC potential, the amplitude and frequency of 
the RF field and the m/z of the ion.14 
 
Tandem MS gives better specificity because daughter ions originate only from 
selected parent ions.15 The advantage of tandem mass spectrometry is that the 
first quadrupole selects a specific molecular ion; the second quadrupole often 
referred to as the collision chamber, introduces a gas, which collides with the 
molecular ion producing increased fragmentation; the third chamber scans the 
predominant ion fragment produced, and hence is highly specific.16 Finally, 
the fragments are passed on to a detector. This is often an electron multiplier 
in which electrons impact on a plate, generating more electrons, which impact 
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on another plate, producing more electrons and so on. The amount of electrons 
produced is proportional to the signal intensity. 
 
A problem with coupling LC and MS, is the relatively high volume of vapour 
that is generated by the evaporation of the mobile phase, and hence, the need 
for high-capacity pumps in the source of the MS. The use of low-dispersion 
tubing, unique interfaces and a range of different ionisation techniques have 
overcome this problem.17 The application of an interface is highly important in 
this area and development has taken a long time.  
 
The most common ionisation method employed in this field of research is 
atmospheric ionisation, which involves removing large amounts of solvent, to 
leave just the ion. This could be by thermospray, electrospray (ESI), or 
atmospheric pressure chemical ionisation (APCI). In recent years, the 
techniques of ESI and APCI have superseded that of thermospray. In 
electrospray, the solution is passed along a stainless steel capillary, which has 
a high voltage applied to the outlet tip (around 3-5 kV). When the solution 
reaches the end of the tube, it is nebulised by the high current and a fine spray 
of ionised droplets emerges. The droplets then pass into a heated evaporation 
chamber where solvent is evaporated from them – aided by flowing nitrogen 
gas at the end of the capillary. The droplets get smaller, which causes them to 
fissure into smaller droplets, until eventually, the droplet is so small that it 
becomes de-solvated. It is then able to pass into the mass analyser.18 In APCI, 
the solvent molecules are ionised by a corona discharge to form chemically 
ionised reagent plasma. In the plasma, protons are transferred to form positive 
and negative ions, due to collisions and charge transfer reactions occurring 
between the solvent and analyte. ESI is regarded as a soft method of 
ionisation, and is a lot more versatile than APCI, as it is able to ionise 
extremely polar, non-volatile molecules, which can be difficult for APCI.16 It 
is vital to have a good ionisation source for clean MS spectra, sensitive 
detection, robustness and reliable operation.19  
 
There are two interfaces used in this report, as during the running of these 
projects, the LC-MS/MS system was upgraded. The original source 
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TurboIonspray, a pneumatically-assisted ESI method, which allows higher 
flow rates with improved sensitivity, is pictured in Figure 1-3 below. Both the 
turbo probe and the ionspray probe are directed at angles of 45° and 135° 
accordingly, with respect to the curtain plate. The turbo probe produces a jet 
of heated dry nitrogen gas, which collides with the spray, produced by the 
ionspray probe (LC-effluent) at an angle of approximately 90°, near the 
orifice. This interaction helps focus the turbo ionspray stream and increases 
the rate of droplet evaporation, resulting in an increased ion signal.20 
 
 
Figure 1-3: Turbo Ionspray Setup20 
 
However, the upgraded model employed two interfaces. It used the original 
TurboIonspray interface coupled to a Hot Source-Induced Desolvated (HS-ID) 
(Ionics, pictured Figure 1-4). The HSID interface was a relatively inexpensive 
way of upgrading the MS, which enabled an increase in sensitivity (at least 
double) and a decrease in background noise. HSID is an atmospheric pressure 
interface which uses orthogonal nebulisation to reduce any non-desolvated 
residues fouling up the ion optics, therefore increasing signal intensity and 
performance of the MS. In the HSID interface, desolvation occurs via direct 
heat transfer from the hot gas as the ions cross a flow path that consists of 
three laminar flow regions and four 90˚ bends, prior to being extracted into the 
low pressure region of the mass spectrometer.21 
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Figure 1-4: Hot Source-Induced Desolvated (HSID) Interface21 
 
In clinical and toxicological studies, LC-MS and LC-MS/MS (tandem mass 
spectrometers) are increasingly used because of their versatility for high-
throughput determinations of drug concentrations in biological samples.3 
Operating in mass reaction monitoring (MRM) mode, low levels of 
compounds in complex biological matrices can be identified and the best 
selectivity is ensured. Recent studies have proved LC-MS/MS (with APCI) to 
be useful in the screening of drugs of abuse, including BZP, in urine. It has 
shown LC-MS/MS to generate reliable results with high sensitivity.22  
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1.2. The Detection and Quantitation of BZP and TFMPP in Blood 
 
1.2.1. Application of Study 
 
The aim of the study was for the Medical Research Institute of New Zealand 
(MRINZ) to provide information to the Ministry of Health (MoH) on the acute 
health effects of BZP and TFMPP measuring cardiovascular and 
psychological functioning, driving performance, and sleep. MoH provided 
funding for this study. Ethics approval was given by the Central Regional 
Ethics Committee and by the University of Waikato Ethics Committee.  
 
Volunteers were recruited through MRINZ by way of posters, advertising at 
shops, university etc. Volunteers were required to be 20 years old or over and 
to have taken party pills containing BZP and TFMPP on at least three 
occasions. People excluded were those with a history of diagnosed psychiatric 
conditions, epilepsy, moderate to severe asthma, hypertension, glaucoma, 
thyroid disorders, diabetes, urinary difficulties, cardiovascular disease or 
lactose intolerance. Those using any medication with an effect on serotonin or 
dopamine were also excluded. This criteria was assessed on an initial visit to 
the hospital.  
 
Subjects were required to avoid the use of any recreational drugs from one 
week before the test day until one week after; to avoid the use of alcohol from 
8 p.m. on the night before the test day, and to fast for a minimum of six hours 
before the start of their test day. 
 
The study required 64 volunteers in total. Each subject was required to 
participate for one full day where they received either (16 subjects each 
group): 
• Two doses of BZP and TFMPP and alcohol 
• Two doses of BZP and TFMPP and orange juice 
• Two doses of a placebo and alcohol 
• Two doses of a placebo and orange juice 
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Volunteers receiving the first and second combinations (above) consumed one 
party pill at time zero and a second two hours later. The total dose of BZP and 
TFMPP received reflected the average recommended consumption. The 
capsules the subjects received were formulated by the hospital pharmacy. 
Three different types of capsules bought over-the-counter at a Wellington 
party pill shop were analysed to quantify levels of BZP and TFMPP. The final 
formulation was a mixture of two of the bought party pills. Methods and 
results for this analysis can be found in Appendix A. The capsules contained 
75 mg of BZP.2HCl and 18 mg of TFMPP.2HCl. Subjects receiving alcohol 
were given six units in total, spread out over three hours (30 mL of vodka = 
one unit).  
 
The volunteers were subjected to numerous tests, including a driving 
simulator and physical tests, to examine the effects of the party pills alone and 
in combination with alcohol. Blood samples were taken before administration 
(baseline) then at 3.5, 6.5 and 10 hrs. These were analysed for alcohol 
(ethanol), BZP and TFMPP levels.  
 
The primary aim of this thesis was to develop, validate, and utilise an LC-
MS/MS method for the detection of BZP and TFMPP in whole blood. A total 
of 256 blood samples were expected to be analysed (for BZP and TFMPP) as 
part of this project using the method developed in this study. 
 
1.2.2. Benzylpiperazine and m-Trifluoromethylphenylpiperazine 
Literature Review 
 
BZP and TFMPP are new designer drugs which have caused controversy, 
especially in New Zealand, due to their legality. According to Encyclopaedia 
Britannica “Designer drugs usually are synthesised for the first time in an 
attempt to create a chemical whose molecular structure differs only slightly 
from that of some well-known controlled substance but whose effects are 
essentially the same. Because of the difference in molecular structure, the 
designer drug, unlike the controlled substance, ordinarily will not be 
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specifically listed as illicit by law-enforcement organisations”.23 A review of 
the limited literature available on BZP and TFMPP is provided below. 
 
1.2.2.1. Legal Status 
 
In New Zealand, BZP and TFMPP are found in a large and diverse range of 
party pills (‘herbals’, ‘energy’ pills) marketed under 150 (or more) brand 
names including Charge, Frenzy, Rapture, Jet and Bliss. Quantities of BZP 
range from approximately 60 mg to 500 mg per tablet and a recommended 
dosage of about 200-300 mg has been given by some manufacturers. The pills 
are readily sold at a variety of different retail outlets such as liquor stores, 
dairies, petrol stations and the internet. It is estimated that 2-3 million 
servings (serving size is based on package recommendations) were sold in 
New Zealand in the year ending 2004.24,25 It was this magnitude of popularity 
that prompted the endorsement of The Misuse Of Drugs Amendment No.3 
Bill in June 2005, creating a new category of controlled, but not illegal 
substances, known as Schedule D. BZP is on this Schedule – making it illegal 
to sell to people under 18 years old, and imposing restrictions on 
advertising.26 
 
The government has decided to provide funding for research into BZP and 
TFMPP in order to make a more considered decision on the legality of the 
drugs. However there is a lot of controversy from opposing members of 
parliament and the public, which has resulted in petitions and other 
movements attempting to make the drugs illegal. The drugs are marketed for 
use as harm-minimisation treatment for users addicted to methamphetamine 
(‘P’) and ecstasy. However, the conflicting dispute, argues that they could 
provide a gateway to harder/illegal drug use. 
 
In the United Kingdom, piperazines are classed as a prescription only 
medicine. The status of BZP is yet to be determined, however sales of the 
drugs have been suspended by the MHRA (Medicines and Health Care 
Products Regulatory Agency), until further notice. The drugs could be 
purchased from ‘head shops’ and the internet, marketed as ‘pep’ pills. In the 
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United States, the Drug Enforcement Administration (DEA) made a final 
decision to place BZP including its salts, isomers and salts of isomers into 
Schedule 1 (drugs which have no medical use and a high level of abuse 
potential) of the Controlled Substances Act (CSA).27 TFMPP was temporarily 
scheduled, but later removed, as it does not demonstrate the same abuse 
potential as BZP. After an increased number of encounters of BZP and 
TFMPP in Japan, it was banned under the Narcotics and Psychotropics 
Control Law, 2003,28 and it is regulated (under the Act on the Prohibition of 
Certain Goods Dangerous to the Health) in Sweden.29 
 
On 1st September 2006, Australia added BZP and TFMPP to Schedule 9 
(prohibited substances) of the Standard for Uniform Scheduling of Drugs and 
Poisons (SUSDP) as decided by the National Drugs and Poisons Schedule 
Committee (NDPSC).30 Victoria was the last State in Australia to illegalise 
BZP following this ruling. 
 
1.2.2.2. History 
 
BZP was first synthesised by Wellcome Research Laboratories for use as an 
anthelminthic (anti-parasitic) mainly used in cattle. Subsequent studies found 
it reversed the sedative effects of tetrabenazine (a dopamine depleting drug) in 
rats and mice, leading to the suggestion that BZP use may exhibit 
antidepressant activity as it affects monoamine accumulation.31 
 
Trials (performed by EGIS Pharmaceutical Works, Hungary) were carried out 
on its effectiveness as an antidepressant. The trial drug was known as Trelibit, 
its main constituent being EGYT-475 or N-benzyl-piperazine-
picolinylfumarate. However, studies on its biochemical mode of action found 
that its metabolite EGYT-2760 or BZP had a high-affinity uptake of 
noradrenaline, dopamine and serotonin. Hence Trelibet itself was regarded as 
inactive and BZP was concluded to be more like amphetamine, exhibiting a 
serotonin uptake inhibition and receptor agonistic effect.32,33 After studies 
concluded its effects were in fact very similar to that of dexamphetamine, 
clinical research on BZP was stopped.34 
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It was not until the 1990s that the use of BZP as a recreational drug became 
more apparent and with its legal status undetermined, use spread worldwide. 
In New Zealand, the drug was formally marketed by Matt Bowden with the 
creation of pharmaceutical company Stargate International (estabilished circa 
1999), involved in the manufacture and distribution of BZP and similar 
products, as harm-minimisation tools. This actuated the establishment of the 
Social Tonics Association of New Zealand (STANZ), which provided 
recommendations to the Health Select Committee advising regulations 
regarding the use of new legal recreational drugs.35 The BZP party pills 
industry has grown incredibly from this point forward and it is this escalation 
in prevalence which has led to the need for intensive research to be carried out 
on the pharmacological effects of these drugs. 
 
1.2.2.3. Neurological and Health Effects 
 
BZP is a sympathomimetic drug,25 meaning, it produces physiological effects 
which resemble those caused by the stimulation of the sympathetic nervous 
system (SNS). The SNS is responsible for secreting adrenaline and 
norepinephrine (or noradrenaline) in a sympathico-adrenal response (fight or 
flight response). 
 
Research has shown that BZP has three main mechanisms of action. It affects 
the reuptake of noradrenaline (NA), the reuptake inhibition and stimulation-
independent release of dopamine (DA), and exhibits an uptake-inhibition 
effect and a receptor agonistic effect on serotonin (5-hydroxytryptamine, 5-
HT)33. NA, DA and 5-HT are all monoamine neurotransmitters, which are 
responsible for nerve responses in the body and brain. The effect on DA 
appears to be the main action of BZP, with 5-HT and NA playing a lesser 
role, with the latter mainly being responsible for the peripheral effects being 
the main mediator of the SNS.36 
 
Tests on EGYT-475 and its metabolite EGYT-2760 using rat stomach fundus  
for the study of serotoninergic mechanisms, indicated BZP had 5-HT 
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agonistic and antagonistic actions. BZP was found to cause a dose-dependent 
inhibition of the 5-HT induced contractions and at higher concentrations 
displayed agonistic activity on the rat fundus preparation.37 BZP also 
demonstrated a strong inhibitory action on the high-affinity uptake of 5-HT in 
rat hippocampus,33 and increased both the resting and the nerve-evoked 
release of NA in peripheral sympathetic nerve fibres (of rabbits).38  
 
Tests comparing MDMA and piperazines BZP and TFMPP in rats showed 
that in vivo BZP released [3H]MPP+ (DA transporter (DAT) mediated release 
assay) and also caused elevations in 5-HT (however to a much lesser extent). 
TFMPP was the opposite and released [3H]5-HT (serotonin transporter 
(SERT) mediated release assay) with no effect on DA. When administered 
together they mimicked the monoamine release of MDMA, however to a 
much lesser extent (3-fold less potent).39,40 It has been noted that 
manufacturers of the drugs combine the two stimulants to recreate the effects 
of ecstasy. Tablets are usually found to contain varying ratios of BZP and 
TFMPP with a 3:1 ratio usually found in the U.S.A.41 
 
TFMPP was found to display full agonist activity at multiple 5-HT receptors, 
partial agonist or antagonist activity at 5-HT2A receptors, and SERT 
mediated 5-HT releasing activity.40 There have been a few studies on the 
serotoninergic properties of TFMPP, for example its ability to moderately 
reduce the frequency of spontaneous motor seizures in rats with pilocarpine-
induced epilepsy.42 In rats, TFMPP increased concentrations of the hormones 
corticosterone (in plasma), adrenocorticotropin (ACTH) and prolactin and 
decreased CRH (corticotrophin releasing hormone) in the hypothalamus (in 
rats) by way of 5-HT antagonist-susceptible mechanism.43 These hormones 
are normally released in response to physical, emotional or chemical stress. 
Also, in rats, TFMPP has been found to produce dose-dependent decreases in 
food intake, body temperature, and spontaneous ambulatory motor activity. 
Detailed information on the neurochemical, physiological, cardiovascular and 
locomotor effects of TFMPP can be found in the review by Murphy et al.43 
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Some tests on behaviour (in humans, rats and primates) have been conducted, 
which showed BZP produces considerable increases in heart rate, systolic 
blood pressure, diastolic blood pressure (to a lesser extent) and pupil size. 
Other side effects (fewer cases) were flushing and sweating. In a double-blind 
placebo controlled study, former amphetamine addicts found BZP and 
dexamphetamine indistinguishable, administered in a 10:1 ratio.44,34 At a high 
intake level, monkeys experienced involuntary head movements, jaw 
chattering, bizarre body postures and hyperactivity. The behavioural effects 
were suggested to be long-lasting in the monkeys.31 Supporting this, BZP was 
also found to have significant effect on ambulation (continuous circling of the 
cage, and sniffing) in rats.40 In tests where TFMPP and BZP were 
administered together at high dosages (10mg/kg in rats) several rats were 
found to develop short-lived seizures. This was not observed after 
administration of the individual drugs, suggesting that BZP and TFMPP may 
have a synergistic effect when administered together in vivo, possibly due to 
pharmacokinetic factors.39 
 
BZP was self-administered by primates, although when administered with 
TFMPP, self-administration was significantly decreased. When TFMPP was 
administered twenty minutes prior to cocaine self administration, the pre-
treatment suppressed the cocaine-maintained response.31 In studies using rats, 
BZP induced place preference, which leads to the conclusion that the drug 
possesses rewarding properties.45 This suggests BZP may exhibit abuse 
liability of the amphetamine type – although this is not the case for TFMPP. 
 
A study carried out in New Zealand suggested that early BZP use caused 
heightened anxiety later on in rats.46 BZP was administered to rats at the 
periadolescent stage (equivalent to adolescence in humans) at a dose of 10 
mg/kg for ten days. Seventeen days after the last dose of BZP, the rats were 
subjected to behavioural tests. The preliminary results indicated that the BZP 
administered during adolescence caused higher anxiety levels in the rats 
during adulthood. 
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In a recent study (2005) carried out in Christchurch, it was revealed that 
during a five month period, 61 patients on 80 occasions were admitted to the 
emergency ward (Christchurch Hospital) after ingestion of party pills, 
containing various amounts of BZP. None of these cases proved fatal but a 
few resulted in the patients being admitted to an intensive care unit. The study 
described the toxic effects as palpitations, agitation, nausea, vomiting, 
confusion and collapse, with a few severe cases even resulting in seizures.25 
However the concentrations of BZP and/or TFMPP in patients are not known. 
It is also worth noting that during this period retailers were supplying party 
pills containing up to 1000 mg of BZP in Christchurch, possibly contributing 
to the severity of the adverse reactions in these cases.  
 
This study and a survey carried out in the emergency department at Waikato 
Hospital47 suggest that the main age range for consumption of these drugs is 
from about fifteen years old through to early twenties. The use of alcohol was 
also a common factor, with the reports showing that 49% and 66.4% 
respectively of users had mixed the two substances. The effect of the 
consumption of alcohol (which is not recommended, according to 
package/manufacturer specifications) with the party pills is currently 
unknown. A national (New Zealand) survey carried out by the Centre for 
Social and Health Outcomes Research and Evaluation (SHORE)48 at Massey 
University supports these findings. The level of party pill use was the highest 
for people aged 18-24 years old, with 33.9% of them having used party pills 
in the preceding year. Nearly nine out of ten users self-reported that they used 
other substances with the party pills, with 91% reporting having used alcohol. 
 
Two severe adverse effects have been reported in one-off cases. One user (17 
years old) of the party pills (who also consumed a small amount of alcohol) 
was admitted to the emergency ward at Waikato hospital presenting with 
symptoms of acute renal failure. It was postulated that the kidney failure was 
a direct result of the toxicity of the party pills, however use of party pills was 
not confirmed by analysis.49 A 20 year old male developed an acute psychotic 
episode (including delusional beliefs and auditory and visual hallucinations) 
that led to him setting fire to his room. The man was admitted to an acute 
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inpatient psychiatric unit, and symptoms had completely subsided within 48 
hours. It is thought that the ingestion of four tablets of rapture (self-reported) 
was the main cause of this episode, however, the man had also reported using 
nitrous oxide and a small quantity of cannabis.50 
 
There have been two reported deaths where the use of BZP has been noted. A 
23 year old woman (in Switzerland) was hospitalised 11 hours after ingestion 
of BZP and 7 hours after ingestion of MDMA, plus large quantities of water. 
She died shortly after hospitalisation due to swelling of the brain caused by 
hyponatriemia, (a drop in sodium levels, in plasma) due to water 
intoxication.51 However, the contribution that BZP made to the death cannot 
be confirmed, as these are common adverse effects relating to the intake of 
MDMA. The second case was in Sweden, where a 22 year old male died. GC-
MS analysis showed a level of 1.7 µg/g blood of BZP; ecstasy, cannabis and 
3,4-methylenedioxyamphetamine (MDA, a psychotropic drug said to be 
similar to ecstasy) were also detected. MDA is also a metabolite of ecstasy.29 
BZP was said to have contributed to the case but the exact role was not clear. 
 
1.2.2.4. Structure, Detection and Metabolism 
 
BZP is an entirely synthetic, N-monosubstituted piperazine with a structure 
similar to that of amphetamine as shown in Figure 1-5. The piperazine (1,4-
diazacyclohexane) functional group is a six-membered heterocycle that 
contains two secondary amine groups. Piperazines have many medicinal uses 
such as anti-allergy, antibiotics, analgesics and cancer treatments, for example 
imatinib mesylate ( Figure 1-5) is used for the treatment of leukaemia. 
However more recently, piperazines have been found in the form of 
recreational drugs, such as m-chlorophenylpiperazine (mCPP), 1-(3,4-
methylenedioxybenzyl)piperazine (MDBP), 1-(4-methoxyphenyl)piperazine 
(MeOPP) and the more common BZP and TFMPP. BZP is normally found as 
a base (yellow-green liquid) or a hydrochloride salt (white solid). BZP in the 
free base form is corrosive and causes burns; it is also an irritant to the eyes 
and respiratory system.52 TFMPP is found as a hydrochloride salt (yellowish 
solid) or a colourless liquid. Both substances are primarily used as chemical 
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intermediates in the production of certain detergents and pharmaceuticals,28 
but have no known human medicinal uses.  
 
In the early nineties, due to its stimulating properties, BZP became 
increasingly widespread as a ‘rave’ drug. With increasing popularity, came 
escalating concern regarding the safety of these drugs. The danger with new 
recreational drugs is that they have not been subjected to clinical tests and 
therefore the safety level of the drugs cannot be certain. Research has been 
documented over the last 10-15 years on different aspects of these new drugs, 
however this is insufficient to draw conclusions on their appropriate legal 
status. 
 
Various analytical procedures for the detection of recreationally used 
piperazines were explored in 2001. This included immunoassays, HPLC-UV, 
GC-NPD and GC-MS, in which the latter two methods proved useful for 
determining the contents of a BZP capsule.53 More recent methods for the 
detection of BZP and TFMPP in biological samples have been documented. 
These include GC-MS for the detection and quantitation of the drugs in 
plasma,54 GC-MS,55 LC-ESI-MS55 and LC-MS-MS22,56 for the detection of 
BZP and other abuse-liable drugs in urine and chiral capillary electrophoresis 
for the separation of amphetamines and piperazines in spiked urine and 
synthetic samples.57 
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Figure 1-5: Structures of BZP, TFMPP, Piperazine, Amphetamine, Methamphetamine, 
MDMA, and Imatinib Mesylate 
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Studies on the metabolism (in rats) of BZP were carried out by Staack et al. in 
about 2002,58 and further studies using GC-MS and LC-MS have confirmed 
the major metabolites.55 The identified metabolites indicated that BZP was 
hydroxylated in the aromatic ring and that the piperazine moiety is 
metabolically degraded. Apart from the principal metabolite 4-hydroxy-BZP 
(2), 3-hydroxy-BZP (3), 4-hydroxy-3-methoxy-BZP (4), piperazine (5), 
benzylamine (6), and N-benzylethylene diamine (7)58 were also identified 
(Figure 1-6). The primary metabolite 4-hydroxy-BZP is conjugated into the 
glucuronide and a smaller portion is metabolised into the sulphate.59 
 
By comparison with BZP, the metabolism of TFMPP has been more 
extensively researched. The metabolic pathway of TFMPP (in rats) is as 
shown in Figure 1-7. TFMPP is extensively metabolised, and almost 
exclusively excreted as metabolites. The main metabolite is hydroxy-TFMPP 
(2) formed by aromatic hydroxylation, catalysed by cytochrome P-450 
enzymes (CYP, or more specifically CYP2D6)60 followed by glucuronidation 
(about 70%) or sulphation.28,61 However in humans the conjugation of phenol 
into the sulphate is generally more extensive, so it is possible that this may be 
the phase II metabolic pathway for TFMPP and also BZP.28 For reference, 
Phase I of drug metabolism involves the oxidation, reduction or hydrolysis of 
a molecule to form a polar functional group. Phase II reactions are known as 
conjugation reactions and usually involve the polar functional groups formed 
at Phase I.  
 
Other minor metabolic pathways of TFMPP are the degradation of the 
piperazine heterocycle by double N-dealkylation of TFMPP to N-(3-
trifluoromethylphenyl)-ethylenediamine (3) or to 3-trifluoromethylaniline (6); 
degradation of hydroxy-TFMPP to N-(hydroxy-3-trifluoromethylphenyl)-
ethylenediamine (4) or to hydroxy-3-trifluoromethylaniline (5) followed by 
partial N-acetylation of the anilines (7 - 8).62 
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1.3. Detection of Multiple Recreational Drugs in Hair 
 
1.3.1. Application of Study 
 
Detection of drugs in hair is proving very valuable as it is non-invasive and 
can provide a history of drug use. Determining a person’s drug history is 
important in drug-related deaths, as it can help establish whether or not they 
were a chronic or naive user, which can often shed some light as to why they 
might have died. Also, detection in hair can help determine whether someone 
may have been using particular drugs at the time of an earlier (criminal) 
incident. This can help support or refute other information. Other applications 
of hair analysis involve child custody disputes and drink spiking incidents.6 
  
GC-MS is a popular choice for multiple drug analysis, as well as other 
forensic applications. Many successful GC-MS methods for the detection of 
multiple drugs in biological specimens have been documented,63,64,65,66 due to 
its sensitivity and also due to the availability of large libraries of standardised 
mass spectra. LC-MS is becoming more popular due to its ability to analyse a 
wide range of compounds with great sensitivity and a variety of literature 
(including a detailed review by Maurer3) exists showing its versatility to 
detect multiple classes of drugs in plasma and oral fluid3,15,67,68,69 as well as in 
hair.6,70 It appears that GC-MS is the most common type of analysis for the 
detection of drugs in hair, with very few methods published using LC-MS. 
 
The secondary aim of this thesis is to develop a method ideally to 
simultaneously detect and quantitate multiple recreational drugs in hair using 
LC-MS/MS. Drugs to be analysed are methamphetamine, amphetamine, 
MDMA, MDA, BZP, morphine, codeine and 6-MAM. 
 
1.3.2. Illegal Recreational Drugs 
 
There are many types of illegal drugs used/abused for recreational purposes, 
however the most common are the amphetamine type compounds 
(methamphetamine, MDMA) and the opiates. The United Nations Office on 
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Drugs and Crime, World Drugs Report 2006,71 details the worldwide use of 
these illegal drugs and is summarised in Figure 1-8.  
 
Although New Zealand’s main illegal drug use is associated with cannabis 
(marijuana), the use of stimulants such as ecstasy and amphetamines and the 
use of opiates, is growing. Figure 1-9 shows different drug types and the 
proportion of New Zealanders that have ever tried or used them in the last 12 
months,72 including the legal drugs alcohol and tobacco. The need for reliable 
detection of these illicit drugs is important, and is often used in court for 
charges relating to possession and manufacture, workplace drug testing and 
toxicology.  
 
Vast amounts of research have been carried out on the above-mentioned drugs 
(especially in comparison to BZP and TFMPP, which are relatively new to the 
drug scene). A brief introduction to the drugs that can be detected in hair by 
LC-MS/MS is included below along with their structures and mechanisms of 
action. 
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Figure 1-9: New Zealand Drug Statistics 1998.72 Proportion of New Zealanders who 
have ever tried or recreationally used different types of drugs, in the last 12 months. 
 
1.3.2.1. Amphetamine Derived Compounds 
 
Methamphetamine (MA) (the structures of amphetamine, methamphetamine 
and MDMA are shown in Figure 1-5, page 23) is a synthetic, white, bitter-
tasting powder or crystalline salt. L-methamphetamine (levo-
methamphetamine) is widely used in nasal decongestants, such as the Vicks 
Inhaler, however it has no stimulant or addictive properties. The D- (dextro-
methamphetamine) isomer is known to be a very addictive stimulant drug and 
use appears to be widespread. Short-term effects include increased heart rate 
and blood pressure, increased activity, a euphoric or ‘rush’ feeling and a loss 
of appetite.73 
 
Methamphetamine has been called a problem drug in some countries, due to 
its highly addictive properties and its ability to cause aggressive tendencies or 
psychosis in humans.74 In 2002, New Zealand’s MA use dramatically 
increased (according to household drug surveys), and in 2003 MA was 
reclassified (from Class B) to a Class A drug in New Zealand (under the 
Misuse of Drugs Act 1975).75 In the United States however, it is a Schedule II 
drug on the CSA, as it possesses some medicinal properties. MA is prescribed 
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in the United States for the treatment of narcolepsy, attention deficit disorder 
and for short-term treatment of obesity.73 
 
Methylenedioxymethamphetamine (MDMA, ecstasy) is a synthetic, 
psychoactive drug with hallucinogenic properties. It is normally formulated 
into tablets which often contain harmful adulterants.76 The physical effects of 
MDMA are similar to those of MA, although users also feel an increased level 
of sociability, sense of wellness and insightfulness. MDMA was legal up until 
1985 and was commonly found in bars and gay clubs and increasingly found 
at ‘raves’.77 It is currently illegal in most countries; it is a Class A drug in the 
United Kingdom and New Zealand, and a Schedule I drug in the United 
States. 
 
3,4-Methylenedioxyamphetamine (MDA, ‘love drug’, Figure 1-10) is also a 
stimulant which is commonly abused. It is a metabolite of MDMA, and hence 
has the same legal status as MDMA. Initially it was used as a cough 
suppressant, ataractic (sedative) and anorexigenic (appetite suppressant) drug. 
In the 1970s, abuse became widespread with reports of deaths in California 
and Canada.78 It is commonly found in combination with MDMA. Often so-
called “ecstasy” tablets contain a mixture of MDMA, MDA, 
methamphetamine and other adulterants. This cocktail can be lethal and often 
users of these drugs are unaware of what they are taking. 
 
 
 
 
 
 
In the 1960s, amphetamine abuse was associated with psychosis and central 
nervous system disorders. Amphetamine is known to induce monoamine 
release by disruption of vesicular storage and transporter reversal. MA causes 
Figure 1-10: Structure of Methylenedioxyamphetamine (MDA) 
Methylenedioxyamphetamine (MDA) 
O 
O NH2 
CH3 
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dose-dependent releases of DA, NA and 5-HT, with it having a less potent 
effect on the latter.79 The release of DA by DAT and also a considerable 
release of 5-HT via SERT are responsible for the behaviour and locomotor 
effects of MA.80 Research in rats, primates and humans has shown that 
multiple doses of MA cause long-lasting depletions of DA and 5-HT, marked 
decreases in the activity of tyrosine hydroxylase and tryptophan hydroxylase 
(enzymes responsible for the biosynthesis of DA and NA and the regulation of 
5-HT respectively), the concentration of DA and 5-HT metabolites, and the 
number of DA and 5-HT transporters.81,82 In rats, multiple administration of 
MA provoked impaired memory function.81 
 
Similarly MDMA induces both dopamine and serotonin release but with 
reversed priority, with the role of DAT in the behaviour of MDMA being 
questionable.80 MA causes neurotoxicity within the terminal fields of both 
dopaminergic and serotonergic neurons. MDMA induces a similar neurotoxic 
effect but exclusively in serotonergic neurons.80 
 
A survey carried out in New Zealand by SHORE83 showed that one in ten 
New Zealanders aged 18-29 had used an amphetamine type stimulant drug in 
the last year. Amphetamines were the most commonly tried drug (10%) while 
5% had tried ecstasy and 1% had tried crystal MA. The average price of 
ecstasy in New Zealand is $60- $80 per pill, and amphetamine $100-$150 per 
gram. Findings from another study carried out by SHORE75 comparing 
household surveys from various years showed that in 1998, 2.9% of people 
reported that they had used amphetamine in the last year compared with 5% in 
2001 and 4% in 2003. This was said to indicate a levelling off of amphetamine 
use in New Zealand, although this may not be the view of the police and other 
communities. However other countries have reported waves of amphetamine 
epidemics. 
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1.3.2.2. Opiates 
 
Opiates are alkaloids derived from the seed pods of the opium poppy. The 
main opiates include heroin, morphine, codeine and thebaine. In New Zealand 
approximately 4% of the population admitted to having tried opiates (1998 
National Drug Survey).72 Opiates, costing around NZ$1000 per gram,84 are 
relatively expensive compared with the amphetamines. 
 
Morphine is a narcotic analgesic used to treat moderate to severe pain 
especially in cancer patients. It effectively numbs pain and hence is widely 
used as a prescription medicine especially in hospitals. It also alters mood and 
can induce sleep. Side effects include nausea, vomiting, constipation and at 
high doses it can also cause respiratory failure. Morphine is a Class B drug in 
the United Kingdom and New Zealand (Misuse of Drugs Act) and a Schedule 
II drug on the CSA in the United States, as it has medicinal uses. 
Figure 1-11: Structures of Morphine, 6-MAM, Heroin and Codeine 
CH3OCO 
6-Monoacetylmorphine 
(6-MAM) 
Morphine 
Heroin Codeine 
CH3O 
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Codeine (methyl morphine) can be extracted directly from the opium poppy 
but is most commonly synthesised from morphine by O-methylation. It is used 
in analgesic, cough suppressant and antidiarrheal medications. In the liver it is 
converted to morphine by the CYP-450 enzyme CYP2D6.85 Therefore it has a 
similar mechanism to morphine and has a weak affinity for the µ-opioid 
receptor (see below) however is much less potent as only approximately 10% 
is converted.86 In the United States, codeine is a Schedule 2 drug on the CSA 
when sold in formulations by itself, however when sold in preparations with 
paracetamol and aspirin (for pain-relief) it is a Schedule 3 drug. In New 
Zealand it is classified as Class C (pharmacy only medicine) and is available 
without a prescription in combination analgesics containing up to 15 mg/tablet 
usually of a codeine salt such as codeine hydrochloride or codeine phosphate. 
It is commonly used as a recreational drug, most likely due to its ease of 
availability. 
 
Heroin is a semi-synthetic lipophilic morphine derivative formed by the 
acetylation of morphine. The structures of heroin, morphine, codeine and 6-
monoacetylmorphine (6-MAM) are shown in Figure 1-11. In plasma, heroin 
itself is unstable, and it rapidly hydrolyses to 6-MAM and morphine.87 Hence 
the detection of both of these molecules can be used to indicate the presence 
of heroin. Heroin is a Schedule I drug (CSA) in the United States and a Class 
A drug in the United Kingdom, and New Zealand (Misuse of Drugs Act). 
 
Morphine, codeine and heroin work by binding to specific opioid receptors in 
the central nervous system. When activated, the opioid receptors regulate 
responses to pain, stress and emotions. The three main opioid receptors are µ-, 
δ- and κ-, which are activated by endogenous peptides. Each of the opioid 
receptors exist in different parts of the body and are responsible for different 
functions. Research has shown that the µ-receptor agonists display the best 
analgesic activity but also the highest abuse liability, the δ-receptor agonists 
possibly exhibit less addictive potential, while being poor pain-relievers and 
the use of κ-receptor agonists for pain treatment should be restricted to the 
periphery because of the strong distressing properties of these compounds.88 
Many studies have shown that morphine binds to all three opioid receptors, 
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but has a particularly high affinity for the µ-receptor. It appears that the 
biological actions (analgesic properties and side-effects as well as addiction 
potential) of morphine are activated by the interaction of the molecule with the 
µ-receptor.88 
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Chapter 2: Experimental Procedures 
 
2.1. Methods for Detection and Quantitation of BZP and 
TFMPP in Blood 
 
The LC-MS method was based on a method developed by Tsutsumi et al. for 
the testing of BZP and TFMPP,55 and originally used for the detection of 
amphetamines in urine.89 It was modified to ensure better sensitivity and 
shorter run times for the particular equipment used in this study. 
 
2.1.1. Materials And General Procedures 
 
2.1.1.1. Drug Supplies and Reagents 
  
BZP and TFMPP drug standards were obtained from ESR drug stores, and 
made up to concentrated stock standards (see 2.1.1.3 below). All reagents used 
were of analytical grade, except those used for the LC which were of HPLC-
grade. 
 
2.1.1.2. 0.1M Phosphate Buffer 
 
0.1 M Phosphate buffer is used in the solid phase extraction, described below. 
The buffer was made by ESR technicians on a regular basis and was always 
less than 1 month old). 13.61 g of KH2PO4 (potassium dihydrogenphosphate) 
in 900 mL of distilled water, is adjusted to pH 6 with 1 M KOH (potassium 
hydroxide). Distilled water is added to make a final volume of 1000 mL. 
 
2.1.1.3. Stock Standards 
  
For initial validation, a stock standard containing a desired concentration of 1 
mg/mL of BZP and TFMPP in ethanol was prepared. Stock standards for BZP 
and TFMPP were made up to desired concentrations 1 mg/mL and 0.5 mg/mL 
respectively, for standards used in quantitation of subjects. 
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2.1.1.4. Internal Standards 
 
Biological matrices from different sources/individuals may have varying 
effects on the drug specimen leading to inconsistent quantitative results. This 
can be accounted for by using deuterated analogues of the drugs, as they have 
almost identical physico-chemical properties to the drugs being identified. 
Therefore, by adding the internal standard to the sample before analysis, it 
will be present throughout the entire analytical process, compensating for any 
loss of the drugs during the process.90 It was desired that both deuterated 
analogues of BZP and TFMPP be used. The deuterated compounds obtained 
were BZP-d7 and TFMPP-d4. Stock standard solutions of 1 mg/mL were 
made up and then diluted to reach desired internal standard concentrations of 
25 ng/mL in 0.2 mL of blood for TFMPP and 200 ng/mL in 0.2 mL of blood 
for BZP.  
 
2.1.2. Sample preparation - Solid Phase Extraction 
 
50 µL of internal standard was added to 200 µL of sample, the samples were 
briefly vortexed and equilibrated for 10 minutes. After addition of 1.5 mL of 
0.1 M phosphate buffer (pH 6) the samples were sonicated for 15 minutes and 
centrifuged at 2700 rpm for 10 minutes. Solid Phase Extraction was carried 
out on 60 mg/3 mL Phenomenex Strata-X 33 µm polymeric sorbent columns, 
on an automated Gilson ASPEC XL4 Robot system. The cartridges were pre-
conditioned with 2 mL of methanol and 2 mL of 0.1 M phosphate buffer (pH 
6). 1.5 mL of sample was loaded on to the column which was then washed 
successively with water (2 mL), 0.01 M acetic acid (2 mL), and 5% aqueous 
acetonitrile (2.1 mL). The column was dried for 3 minutes and the analytes 
eluted with 0.7 mL acetonitrile. 200 µL of 100 mM ammonium formate with 
0.03% formic acid (pH 3.5) was added to the collected fraction and 10 µL was 
injected into the LC-MS/MS system.  
 
2.1.3. Liquid Chromatography-Mass Spectrometry 
 
The LC system consisted of a Shimadzu autosampler, pump, and triple 
quadrupole LC-MS/MS mass spectrometer (API 300, Perkin-Elmer Sciex 
- 38 - 
Instruments) with a TurboIonspray interface. An Apple Macintosh System 8.1 
with Sample control 1.4 software controlled the system. The chromatography 
was carried out on a SCX (strong cation exchange) column (2.0 mm i.d. x 150 
mm, Luna 5µ SCX 100Ǻ, Phenomenex) with column temperature set at 35 ºC. 
The mobile phase was 100 mM ammonium formate with 0.03% formic acid 
(pH 3.5) – acetonitrile (25:75), with a flow rate of 200 µL/min, and a run time 
of 11 minutes per sample. AutoTune software was used to optimise state file 
MS parameters for target compounds. However it does not affect the ion spray 
voltage, the values for the gases or temperature - these have to be adjusted 
manually. The parameters for the MS were as displayed in Table 2-1.  
 
Table 2-1: State File Parameters for API 300 LC-MS/MS 
Gases 
Nebuliser Gas (NEB) 12 
Curtain Gas (CUR) 11 
CAD Gas (CAD) 3 
Controls 
Ion Spray Voltage (IS) 5500 
TEM 450 
Orifice Voltage (OR) 36 
Focusing Ring Voltage (RNG) 160 
High Pressure Entrance Quadrupole (Q0) -6 
Inter-Quadrupole Lens 1 (IQ1) -7 
Prefilters (ST) -11 
First Resolving Quadrupole (RO1) -7 
Inter-Quadrupole Lens 2 (IQ2) -32 
Collision Cell Quadrupole (RO2) -37 
Inter-Quadrupole Lens 3 (IQ3) -63 
Last Resolving Quadrupole (RO3) -42 
Deflector (DF) -150 
Channel Electron Multiplier (CEM) 2400 
 
2.1.3.1. Mass Reaction Monitoring 
 
The MS was carried out in MRM (mass reaction monitoring) mode. This is a 
common scan type in MS/MS, which looks at molecular ion and product ion 
fragments (fragmentation patterns can be found in Appendix B). The 
following transitions were monitored (Table 2-2). 
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Table 2-2: LC Retention Times and MRM Transitions Monitored for Quantitation 
Compound Retention time (min) Transition Monitored (m/z) 
BZP 9.33 177.4 " 91.0 
BZP-d7 9.80 184.4 " 98.0 
TFMPP 5.39 231.4 " 188.0 
TFMPP-d4 5.37 235.0 " 190.0 
 
  
2.1.4. Validation 
 
It is essential to ensure that a method works as intended, precisely and 
accurately. This is achieved by measuring a variety of parameters: selectivity 
(specificity), precision (repeatability and reproducibility), accuracy, linearity, 
range, limit of detection, limit of quantification, and stability.91 
 
A calibration curve was constructed using a series of points and plotting 
concentration versus area ratio of drug to internal standard. Good linearity is 
an indication of accuracy and demonstrates that the results are directly 
proportional to the concentrations.91 Also, an intercept not significantly 
different from zero is important to ensure that there is no significant 
interference from co-extractants. All calibration curves were forced through 
zero, as a blank (zero) standard was used for the analysis. 
 
The reproducibility was demonstrated by running the experiment on three 
different days. The repeatability was determined by carrying out a series of 
five replicate standards each day at a low concentration of BZP and TFMPP 
(52.3 ng/mL and 7.2 ng/mL respectively). Comparing calculated and known 
concentration values and showing good agreement between them, assessed 
accuracy. Accuracy was calculated by the following equation, expressed as a 
percentage where 100% represents excellent accuracy: 
 
Accuracy (%)  =  100×S
Dix
 
Where: Dix  = mean of the determined concentration 
 
S
 = nominal concentration 
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The recovery of the analytes (extraction efficiency) was measured by 
comparing drug concentrations in samples spiked before extraction compared 
with the concentrations of drugs spiked into the reconstituted extract. A series 
of five extraction samples was prepared by adding 35 µL of BZP and TFMPP 
standard ([BZP] = 52.3 ng/mL and [TFMPP] = 7.2 ng/mL) and 50 µL of 
internal standard to 0.2 mL of blank blood then extracting. A series of five 
control samples was prepared by extracting 0.2 mL blank blood and adding 
the same quantity as for the extraction samples, after extraction. The 
extraction efficiency was calculated by the following equation: 
 
Extraction Efficiency (%) =      Area of extracted drug             x100 
  Area of unextracted control samples 
 
 
Stability is important as the drugs can decompose during sample preparation, 
extraction, quantitation and storage. Stability was determined by LC-MS/MS 
analysis of a prepared standard sample (extracted and left at room temperature 
in LC-MS solvent) over a period of one month.  
 
Selectivity is extremely important in forensic applications, as the identity of 
the drug must be ensured. LC-MS/MS not only gives a valid retention time 
but also a mass spectral “fingerprint”, and hence is highly specific. 
 
The coefficient of variation (CV) indicates the variability around the mean in 
relation to the size of the mean, and is defined as: 
  
 CV (%) =100% x Standard deviation 
   Mean 
 
 
By determining the within (intra-) and between (inter-) day CVs, which 
should not exceed 20%, precision, accuracy, and sensitivity is demonstrated 
and the analytical method can be deemed acceptable.91 
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2.1.5. Samples 
 
A trial was carried out by MRINZ on the effects of BZP and TFMPP in 
combination with and without alcohol. Subjects were given two doses of 
BZP/TFMPP or a placebo, either with alcohol (6 units) or orange juice. The 
subjects were assessed on their ability to drive (using a STISM driving 
simulator). Systolic and diastolic blood pressure, heart rate and temperature 
were constantly measured. 
 
Blood samples taken at baseline, 3.5, 6.5 and 10 hours were collected by Dr. 
Imogen Thompson (MRINZ), and sent to ESR for analysis. An anti-coagulant 
(EDTA, ethylenediaminetetraacetic acid) was added to the blood and the 
samples were stored in the refrigerator for up to one week prior to testing then 
frozen at -80ºC. 
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2.2. Methods for Detection and Quantitation of Recreational 
Drugs in Hair 
 
 
The current method employed at ESR for the detection of amphetamine and 
methamphetamine in hair is GC-MS. The preparation and washing of the hair 
used in the original method was kept the same, however the method for 
extraction of drugs from hair was developed based on a published method for 
the extraction of opiates from hair.92 The LC-MS/MS method used was the 
same as the method described in section 2.1.3 for BZP and TFMPP, and was 
modified to accommodate multiple drugs. 
 
2.2.1. Materials and General Procedures 
 
2.2.1.1. Drug Supplies and Reagents 
 
All drugs standards (except MDMA, which is supplied in solution) were 
obtained from ESR drug stores as powders (salts), and made up in 1 mg/mL 
solutions by ESR technicians (stored for up to one year at 4˚C). 
 
All solvents were of analytical grade except acetonitrile used in the 
chromatography (HPLC grade).  
 
Acid solutions and base solutions were stored at room temperature for up to 6 
months, except NaOH, which was kept for up to a month. 
 
2.2.1.2. Stock Standards 
 
A 10 µg/mL stock solution (stored for one month) was made up by diluting 1 
mg/mL solutions (prepared by ESR technicians) of methamphetamine, 
amphetamine, MDMA, MDA, BZP, morphine, 6-MAM and codeine. Diluted 
solutions in methanol were made for each extraction and used for spiking of 
blank hair for the standard curve. A 1 mg/mL stock solution of phentermine, 
made up by ESR technicians, was diluted in methanol, and used to check for 
interference. 
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2.2.1.3. Check Solution 
 
1mg/mL stock solutions of all drugs were diluted to 1 µg/mL and used as the 
check solution for all three validation runs. 
 
2.2.1.4. Internal Standards 
 
A 1 µg/mL solution in methanol was used, containing the following deuterated 
internal standards: methamphetamine-d5, amphetamine-d5, MDMA-d5, 
MDA-d5, BZP-d7, morphine-d3, codeine-d3 and 6-MAM-d3. 50 µL of the 
stock standard was added to each sample. 
 
2.2.2. Extraction of Drugs from Hair 
 
2.2.2.1. Sample Preparation 
 
A 8 mm (diameter) tuft of hair was removed from the vertex posterior (rear of 
crown) as close as possible to the scalp and placed in a bag with the scalp end 
correctly labelled. Samples were stored at room temperature until analysis. 
 
Hair samples were tightly wrapped in Glad Wrap, ensuring scalp ends were 
tightly aligned with the edge of the film. Hair was divided into 2 cm sections 
up to 10 cm (from scalp end), and cut using sharp scissors. Cut sections were 
transferred into labelled glass jars, and were then chopped into one millimetre 
(or smaller) pieces with sharp pointed scissors. 
 
2.2.2.2. Decontamination 
 
Finely chopped hair (20 mg) was placed into extraction tubes with methanol 
(1 mL). Tubes were sonicated briefly, left for 5 minutes, then centrifuged at 
2700 rpm for 5 minutes. The methanol washings were removed with a Pasteur 
pipette and either discarded or retained for analysis (washings from at least 
one section were retained, in a test-tube, dried under nitrogen and  
reconstituted as in 2.2.2.6 below). The washing process was repeated twice 
more with methanol.  
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2.2.2.3. Standards 
 
A series of six standards was prepared by spiking blank hair with the drugs of 
interest at the following concentrations (ng/mg): 0, 0.2, 0.5, 1, 10, 50. Tubes 
were left to equilibrate for 15 minutes. 
 
2.2.2.4. Extraction 
 
0.1 M HCl (1 mL) was added to each tube (excluding the tubes containing the 
washings). The tubes were tightly capped, vortexed briefly and then set aside 
overnight at 37˚C. 
 
After centrifugation (2700 rpm, 10 minutes), the extract was adjusted to pH 7 
using 1 M NaOH (100 µL). 1 mL of 0.1 M phosphate buffer (pH 7) was added 
to the tubes, which were then vortexed briefly and centrifuged at 2700 rpm for 
5 minutes.  
 
2.2.2.5. Sample Clean-up: Solid Phase Extraction 
 
Solid Phase Extraction was carried out on Varian Bond Certify columns (130 
mg sorbent mass, 120 µm particle size) on an automated Gilson ASPEC XL4 
Robot system. The cartridges were pre-conditioned with methanol (2 mL) and 
0.1 M phosphate buffer (2 mL, pH 7). Sample (2 mL) was loaded on to the 
column which was then washed successively with water (2 mL), 0.1 M acetic 
acid (1 mL), and methanol (2 mL). The column was dried for 5 minutes and 
the analytes eluted with dichloromethane, propan-2-ol and ammonium 
hydroxide (80:20:2 v/v, (2 x 1 mL)). 
 
50 µL of acid methanol (15 µL of HCl in 25 mL methanol) was added to the 
collected fraction before it was evaporated to dryness under a gentle stream of 
nitrogen. 
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2.2.2.6. Reconstitution 
 
Samples were reconstituted in 100 µl of 75:25 acetonitrile:100 mM 
ammonium formate buffer with 0.03% formic acid, and 10 µL was injected 
into the LC-MS/MS. 
 
2.2.3. Detection and Quantitation by LC-MS/MS 
 
 
The LC system consisted of a Shimadzu autosampler, pump, and triple 
quadrupole LC-MS/MS mass spectrometer (API 300, Perkin-Elmer Sciex 
Instruments) with a TurboIonspray and a HSID interface. The 
chromatography was carried out on a SCX column (Luna 5µ SCX 100Ǻ 15.0 
x 2.0 mm, Phenomenex) with column temperature set at 40ºC. The mobile 
phase was 100 mM ammonium formate with 0.03 % formic acid and 
acetonitrile (25:75) with a flow rate of 200 µL/min, and a run time of 11 
minutes per sample. Analyst 1.4.1 and Dionex Chromatography MS Link 
were used to control the system. The parameters for the MS were as displayed 
in Table 2-3. The declustering potential, collision energy and collision cell 
entrance potential were set differently for each drug as the instrument showed 
more sensitivity towards the amphetamines than the opiates. Final optimised 
settings can be found in Appendix D. 
 
Table 2-3: State File Parameters for API 300 LC-MS/MS 
Gases 
Nebuliser Gas (NEB) 13.0 
Curtain Gas (CUR) 10.0 
CAD Gas (CAD) 3.0 
Controls 
Ion Spray Voltage (IS) 5200.0 
TEM 500.0 
 
 
2.2.3.1. Mass Reaction Monitoring 
 
The MS was carried out in MRM (mass reaction monitoring) mode. This is a 
common scan type in MS/MS and looks at molecular ion and product ion 
fragments (fragmentation patterns can be found in Appendix B). The 
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following transitions were monitored (Table 2-4). Three transitions for each 
drug were monitored to ensure valid identification. Quantitation was based on 
the first fragment ion, and the second and third transitions were used to 
confirm drug presence, measured as a ratio of first transition to the second and 
third transitions. This gives valid identification if the ratio does not deviate 
more than 20%. 
 
Table 2-4: LC Retention Times and MRM Transitions Monitored for Quantitation of 
Multiple Drugs in Hair 
Compound Retention 
time (min) 
Parent 
Ion (m/z) 
Fragment Ions (m/z) 
Methamphetamine 4.89 150.01  91.10, 119.30, 65.20 
Methamphetamine-d5 4.84 155.16 92.10 
Amphetamine 4.88 136.06  91.09, 119.1, 65.07 
Amphetamine-d5 4.86 141.10 93.1 
MDMA 4.70 194.10  163.2, 135.1, 105.1 
MDMA-d5 4.66 199.11 165.1 
MDA 4.72 180.05  163.20, 133.0, 105.10 
MDA-d5 4.68 185.12 168.08 
BZP 8.02 177.12 91.0, 85.20, 65.10 
BZP-d7 8.34 184.20 98.20 
Morphine 8.39 286.12 152.10, 165.20, 183.20 
Morphine-d3 8.38 289.18 152.10 
6-MAM 5.40 328.15 165.11, 211.11, 193.10 
6-MAM-d3 5.39 331.15 165.11 
Codeine 7.63 300.11 165.18, 152.16, 128.16 
Codeine-d3 7.61 303.20 165.10 
Phentermine 4.80 150.01 133.16, 91.12, 65.09 
 
 
2.2.4. Validation 
 
A series of five standards at the following concentrations: 0.2, 0.5, 1, 10, 50 
ng/mL; a blank and a standard containing only internal standard, were used to 
create a calibration curve for each run. The calibration curve was constructed 
- 47 - 
by plotting the ratio of actual analyte concentration:internal standard against 
the ratio of measured analyte area:internal standard.  
 
Five samples containing 25 µL of the check solution described above, were 
used to check accuracy and precision. The inter- and intra- day CVs and the 
accuracy of the method were calculated using the equations shown in 2.1.4 
above. Limits of Detection (LOD) are evaluated as the lowest concentration 
giving a chromatographic peak with the signal to noise ratio S/N = 3. These 
were estimated using the lowest standard (0.2 ng/mg) and baseline noise. 
 
The extraction efficiency was determined by running a series of five 
unextracted control samples at the same concentration as the check samples 
and comparing values. The control samples were prepared by extracting five 
blank hair samples and adding 25 µL of check solution to the samples after 
SPE, drying under nitrogen and reconstituting as above. The extraction 
efficiency was calculated using the equation in 2.1.4 above. 
 
Phentermine has the same molecular weight as methamphetamine and two 
similar transitions. The potential of phentermine to interfere with the 
methamphetamine analysis was therefore assessed by spiking two extracted 
standards at concentrations of 5 ng/mg and 0.5 ng/mg of phentermine (after 
SPE). 
 
2.2.5. Samples 
  
Three samples from methamphetamine cases previously reported by ESR 
were tested using the above method. Originally the three samples had been 
tested by a GC-MS method, regularly used by ESR for the detection of 
methamphetamine and amphetamine in hair. The concentrations of 
methamphetamine in the three samples as detected and quantitated by GC-MS 
are shown in Table 2-5. Sample one had a very low level of methamphetamine 
detected, which was close to cut-off. Two analyses of sample two were carried 
out, showing very close agreement of results with an average of 0.14 ng/mg. 
The third sample contained no traces of methamphetamine. 
- 48 - 
Table 2-5: Concentration of methamphetamine in hair samples as detected (GC-MS) 
previously by ESR 
Sample ID (ESR ID) Concentration determined by GC-MS 
1 (845) 0.06 ng/mg 
2 (159) 0.15, 0.13 ng/mg 
3 (665E) No Drugs Detected 
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Chapter 3: Results 
 
3.1. Results for BZP and TFMPP Blood Analysis for Driving 
Study 
 
3.1.1. Extraction Efficiency – Solid Phase Extraction  
 
The drugs were extracted from blood using solid phase extraction. A series of 
extracted samples (internal standard and spikes added to blood and extracted) 
and unextracted control samples (internal standard and spike added after 
extraction) were prepared. The extraction efficiencies are shown in Table 3-1 
and Table 3-3. The recovery of TFMPP (109 %) was higher than that of BZP 
(63 %), however any loss was compensated by using internal standards. 
Calculated concentrations for extracted and unextracted samples are within 
very close correlation to each other, this is shown in Table 3-2 and Table 3-4.  
 
Table 3-1: BZP Extraction Efficiency 
  Peak Area 
BZP (52.3 ng/mL) Extracted Control 
  30960 45682 
  27342 43638 
  24291 45010 
  31767 44257 
  24827 43148 
Average 27837.40 44347.00 
     
Extraction Efficiency 63%
 
 
Table 3-2: Calculated Concentrations of BZP (using internal standard ratio) in 
Extracted and Control Samples 
BZP (52.3 ng/mL) Extracted Control 
  58.112 52.964 
  59.399 51.109 
  54.152 55.257 
  57.051 48.408 
  59.273 56.398 
Average 57.60 52.83 
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Table 3-3: TFMPP Extraction Efficiency 
 Peak Area 
TFMPP (7.2 ng/mL) Extracted  Control 
  3241 3381 
  3079 2943 
  3220 2925 
  4045 2639 
  2586 2889 
Average 3234.20 2955.40 
     
Extraction Efficiency 109%
 
 
Table 3-4: Calculated Concentration (using internal standard ratio) of TFMPP in 
Extracted and Control Samples 
TFMPP (7.2 ng/mL) Extracted Control 
  6.334 8.527 
  7.063 6.423 
  8.182 6.991 
  7.007 7.230 
  6.995 7.075 
Average 7.12 7.25 
 
3.1.2. Liquid Chromatography – Mass Spectrometry 
 
The chromatography gave good peak shapes and consistent retention times, 
with a total run time of 11 minutes per sample. Chromatograms from standard 
and actual blood samples are shown in Appendix E, Figures E1-5. 
 
3.1.3. Validation 
 
Calibration curves were constructed with seven points (and a blank) by 
plotting concentration versus area ratio of drug to internal standard. All 
calibration curves were forced through zero, as a blank (zero) standard was 
used for the analysis.  
 
Calibration curves (reproduced using actual data) for BZP and TFMPP are 
shown in Figure 3-1 and Figure 3-2. The standard curves were very 
reproducible and accurate, with correlation coefficients of ≥ 0.999. The 
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method was found to be linear over a range of 7 - 7000 ng/mL and 10 - 10000 
ng/mL of BZP and TFMPP respectively. However, after analysis of some 
preliminary blood samples at similar concentrations to that expected in the 
BZP/TFMPP study by MRINZ, a smaller validated range of approximately 30 
– 1500 ng/mL of BZP and 5 – 200 ng/mL of TFMPP was used as the 
standards during sample analysis.  
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Figure 3-1: LC-MS/MS Calibration Curve BZP 
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Figure 3-2: LC-MS/MS Calibration Curve TFMPP 
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Validation was carried out on three different days, using a standard curve 
(BZP 7-7000 ng/mL, TFMPP 10-10000 ng/mL) and five replicate standards 
(BZP 17.7 ng/mL, TFMPP 28.3 ng/mL) each day. Summarised inter- and 
intra-day results are shown in Table 3-5 and Table 3-6 below. For full 
validation data see Appendix C. All inter- and intra- day CVs were below 
10%. The accuracy was greater than 96% for both BZP and TFMPP with BZP 
giving slightly higher results. The smaller linear range (BZP 30-1495 ng/mL, 
TFMPP 4-207 ng/mL) was also validated with CVs below 10% and accuracy 
greater than 90%. 
 
Table 3-5: Summary of Validation Results 
Range: BZP 7 - 7000 ng/mL, TFMPP 10 - 10000 ng/mL 
Compound Mean Std Dev CV Accuracy
        
Intraday results      
BZP 1 (17.7ng/mL) 20.7 1.2 5.8% 116.7%
BZP 2 (17.7ng/mL) 19.5 1.9 9.5% 110.0%
BZP 3 (17.7ng/mL) 19.8 1.3 6.8% 111.6%
        
TFMPP 1 (28.3ng/mL) 27.7 2.1 7.5% 98.0%
TFMPP 2 (28.3ng/mL) 30.8 2.7 8.6% 108.9%
TFMPP 3 (28.3ng/mL) 27.3 2.5 9.0% 96.6%
        
Interday results      
BZP  20.0 1.5 7.4% 112.8%
TFMPP 28.6 2.8 9.6% 101.2%
 
Table 3-6: Summary of Validation Results 
Range: BZP 30-1495 ng/mL, TFMPP 4-207 ng/mL 
Compound Mean Std Dev CV Accuracy
        
Intraday results      
BZP 1 (53.3ng/mL) 51.8 1.2 2.4% 99.1%
BZP 2 (53.3ng/mL) 58.7 0.7 1.1% 112.2%
BZP 3 (53.3ng/mL) 53.6 1.8 3.3% 102.5%
        
TFMPP 1 (7.2ng/mL) 7.1 0.6 7.8% 99.2%
TFMPP 2 (7.2ng/mL) 6.8 0.4 5.5% 94.4%
TFMPP 3 (7.2ng/mL) 6.5 0.6 9.4% 90.2%
        
Interday results      
BZP 54.7 3.2 5.9% 104.6%
TFMPP 6.8 0.6 8.2% 94.6%
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The samples in solution (analysis by LC-MS/MS) proved to be stable within 
analytical variation, with little change observed over a period of one week. 
The internal standard should compensate for the loss and samples prepared for 
LC-MS/MS analysis were always analysed within three days of preparation. 
 
3.1.4. Results from subjects 
 
A randomised double-blind placebo controlled study of the effects of BZP and 
TFMPP alone and in combination with alcohol was conducted by MRINZ. 
The primary investigator for the BZP/TFMPP Ethanol Safety Study, 
conducted by MRINZ, was Dr. Imogen Thompson. The study assessed 
cardiovascular and psychological effects, driving performance, and effects on 
sleep and mood. A total of 64 subjects were to participate in the study, 
however the trial ceased halfway through due to adverse effects experienced 
by 41 % of those administered BZP and TFMPP. 
 
Of the 35 of the 64 subjects who participated; six subjects received the 
placebo, twelve subjects received alcohol, ten subjects received the 
BZP/TFMPP combination and seven subjects received the 
BZP/TFMPP/alcohol combination. 140 Samples were tested for BZP and 
TFMPP (however one subject, who received placebo combination, was 
removed from the study at the discretion of MRINZ). Of these, 48 samples 
contained BZP and TFMPP, the rest were baseline samples or subjects whom 
received the placebo. 
 
The subjects had a median age of 24 (range 20-38) and 22 (62.9 %) were 
male. Each subject who received party pills was given 150 mg of BZP.2HCl 
and 36 mg of TFMPP.2HCl at time zero, then a further 150 mg of BZP.2HCl 
and 36 mg of TFMPP.2HCl at time two hours (resulting in a total dose of 300 
mg BZP.2HCl and 72 mg TFMPP.2HCl). An initial blood sample was taken 
(baseline), then blood samples were taken at 3.5 hours after the first dose (1.5 
hours after the second dose), 6.5 and 10 hours. An actual chromatogram of the 
blood samples (baseline, 3.5, 6.5 and 10 hours) is shown in Appendix E. The 
final results from the 16 subjects who received BZP and TFMPP (17 subjects 
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received BZP/TFMPP however blood samples could not be taken for one 
subject who had a severe reaction) are shown in Table 3-7. 
-
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The box and whiskers graphs shown in Figure 3-3 (BZP) and Figure 3-4 
(TFMPP), show the concentration of the drugs in blood over time. The 
distribution of data is shown clearly, as the graph shows the maximum and 
minimum points, the upper and lower quartiles and the median. 50 % of the 
data is distributed within the box, and trends in the data are clearly shown. At 
3.5 hours the drugs are still not fully absorbed, the concentrations continue to 
increase, with the highest concentrations recorded at 6.5 hours. At 10 hours 
the concentrations have dropped off, but maximum points are still fairly high 
for both drugs. 
 
Figure 3-5 and Figure 3-6 depict the concentrations of BZP and TFMPP in the 
blood at each time period. The error bars represent the standard error of the 
mean calculated by the following equation: 
S.E =
η
σ
 
Where: σ = Standard Deviation and η = Number of samples/data points 
The standard error of the mean provides an estimate of how close the sample 
mean is to the population mean. The error greatly depends on sample size and 
due to the relatively small sample size, the associated errors are fairly large.  
 
The graphs do not demonstrate a true curve. As the subjects received two 
doses of the pills, it is diffcult to determine absorption rates and 
pharmacokinetics, as it becomes quite complicated. One would expect the 
graph to have a small platform between baseline and 3.5 hours (this is where 
the concentrations peak for the first dose). Between 3.5 and 6.5 hours there 
would also be a peak, this is where the drugs reach maximum concentration. 
The drug concentration most likely peaks at around 4-5 hours which is at least 
2 hours after the second dose. 
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Figure 3-5: Concentration of BZP (ng/mL) in Blood over Time (hours). 
Error bars represent the standard error of the mean for 16 individuals. 
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Figure 3-6: Concentration of TFMPP (ng/mL) in Blood over Time (hours). 
Error bars represent the standard error of the mean for 16 individuals. 
 
Driving performance was assessed on a STISIM Driving Simulator. The 
subjects had to undergo a number of real-life situations which assessed their 
ability to follow other cars at a safe distance, maintain a constant speed (and 
the speed limit) and tested their attention to the scenario. The primary outcome 
variable was the Standard Deviation of Lateral Position (SDLP). The less the 
SDLP, the better the driving performance. The results from the driving 
simulator tested at 6.5 hours are shown in Table 3-8. MRINZ reported a 
statistical analysis on the data (using SAS version 9.1, based on a general 
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linear model), which showed that in the baseline model, the BZP/TFMPP 
combination improved driving performance by giving a significantly smaller 
SDLP. Alcohol caused a weak effect, however there was no statistically 
significant interaction between the BZP/TFMPP/juice and the 
BZP/TFMPP/alcohol combinations.93 It is important to note that of the 19 
subjects who received alcohol (either in combination with the party pills or 
alone), only 3 had a small concentration left in the blood at 6.5 hours. 
 
Table 3-8: Treatment effects on the Standard Deviation of Lateral Position (SDLP, cm) 
at 6.5 hours.93  
 
 
Adverse effects were experienced in seven of the seventeen subjects that were 
administered BZP and TFMPP, compared with none experienced in those that 
received the placebo. Four of the subjects with adverse effects received the 
BZP/TFMPP/juice combination and three received the BZP/TFMPP/alcohol 
combination. Effects experienced were severe agitation, anxiety, panic attack 
(which required treatment), hallucinations, vomiting, headaches/migraines, 
fatigue, and confusion. A few of the subjects experienced some mild effects, 
which included headaches, exhaustion and fatigue. The drug concentration in 
the blood bore no relationship to the symptoms experienced.93 
 
Subjects that received the BZP/TFMPP combination (with or without alcohol) 
showed significant increases in their systolic and diastolic blood pressure. 
Heart rate and temperature were slightly elevated in the BZP/TFMPP subjects. 
- 64 - 
The BZP/TFMPP combination caused subjects to have greater difficulty 
getting to sleep on the night of the test day.93 
 
3.2. Results for Recreational Drugs in Hair 
 
3.2.1. Extraction Efficiency 
 
Extraction efficiency was assessed by preparing five unextracted control 
samples, at the same concentration as the check samples, and comparing 
peak area of the unextracted samples with the extracted check samples (see 
Section 2.2.4). The extraction efficiencies of the drugs was greater than  
68 % except for that of 6-MAM which was 36 %. Quantitation of these 
drugs using the deuterium-labelled internal standards adequately 
compensates for such losses. Low recoveries will of course adversely affect 
limits of detection. A summary of extraction efficiencies is shown in Table 
3-9. 
 
Table 3-9: Detection of Drugs in Hair Extraction Efficiencies for SPE  
Extraction Efficiency 
      
  Mean Area Extraction 
  Extracted Unextracted Efficiency 
MDMA 1954000 2634000 74.2% 
Amphetamine 306000 401600 76.2% 
Methamphetamine 378600 505400 74.9% 
BZP 959800 1407600 68.2% 
MDA 637000 833800 76.4% 
Codeine 351400 476200 73.8% 
Morphine 576600 617400 93.4% 
6-MAM 220800 607200 36.4% 
 
3.2.2. Liquid Chromatography – Mass Spectrometry 
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The chromatography gave good peak shapes and consistent retention times, 
with a total run time of 11 minutes per sample. A total ion chromatograph is 
shown in Figure 3-7. 
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3.2.3. Validation 
 
Calibration curves were constructed with five points (and a blank) by plotting 
concentration vs. area ratio of drug to internal standard. All calibration curves 
were forced through zero, as a blank (zero) standard was used for the analysis. 
All analytes had genuine blanks of close to zero (with added internal 
standard). All calibration curves were linear with correlation efficiencies 
≥0.9997, except BZP which was a quadratic (correlation efficiency 0.9999) 
with the highest concentration (50 ng/mg) curving off on all three validation 
runs. The following six figures (Figure 3-8 - Figure 3-15) show example 
calibration curves for all drugs. 
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Figure 3-8: Hair Analysis Calibration Curve for Methamphetamine 
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Figure 3-9: Hair Analysis Calibration Curve for MDMA 
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Figure 3-10: Hair Analysis Calibration Curve for MDA 
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Figure 3-11: Hair Analysis Calibration Curve for BZP 
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Figure 3-12: Hair Analysis Calibration Curve for Amphetamine 
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Figure 3-13: Hair Analysis Calibration Curve for Morphine 
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Figure 3-14: Hair Analysis Calibration Curve for Codeine 
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Figure 3-15: Hair Analysis Calibration Curve for 6-MAM 
 
Valid identification of the drugs, measured using the ratios of the second and 
third transitions monitored by MRM, was ensured, with all ratios consistent. 
The average ratio (all three validation runs) for the second and third transitions 
are shown in Table 3-10, and did not deviate more than 12 %. In reality, the 
transition ratios would be compared to standard samples used that day, 
however this demonstrates that the method is stable for postitive identification. 
Table 3-10: Transition Ion Ratios (Detection of Drugs in Hair) 
 
Average for 
2nd Transtion 
Standard 
Deviation 
Average for 
3rd Transition 
Standard 
Deviation 
Methamphetamine 10.61 1.25 15.43 1.73 
MDMA 2.55 0.10 1.29 0.19 
MDA 1.06 0.03 1.05 0.04 
BZP 1.20 0.05 1.42 0.08 
Amphetamine 1.24 0.09 1.96 0.11 
Morphine 1.09 0.04 1.27 0.08 
Codeine 1.26 0.06 2.35 0.12 
6-MAM 0.78 0.06 1.05 0.09 
 
Intra-day CVs were all below 12 % and inter-day CVs less than 11 %. 
Accuracy was acceptable for all drugs although for amphetamine, it was only 
80 %. A summary of intra-day validation results can be seen in Table 3-11, 
and inter-day validation results are displayed in Table 3-12. Full validation 
results can be found in Appendix C. 
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Table 3-11: Detection of Drugs in Hair Intra-day Validation Results Summary 
Hair Validation Intra-day Summary 
          
  Day r Mean Std Dev CV Actual Conc. Accuracy 
MDMA 1 0.9998 1.22 0.02 1.6% 1.25 97.8 % 
  2 0.9999 1.31 0.03 2.4% 1.25 104.5 % 
  3 0.9997 1.47 0.07 4.8% 1.25 117.8 % 
Amphetamine 1 0.9999 0.82 0.07 9.1% 1.15 71.3 % 
  2 1.0000 0.93 0.02 2.2% 1.15 81.1 % 
  3 1.0000 0.99 0.03 2.7% 1.15 86.0 % 
Methamphetamine 1 1.0000 1.11 0.01 1.3% 1.17 94.9 % 
  2 0.9998 1.30 0.01 1.0% 1.17 111.5 % 
  3 0.9999 1.32 0.04 3.1% 1.17 113.0 % 
BZP 1 1.0000 1.35 0.07 5.2% 1.25 108.0 % 
  2 1.0000 1.23 0.02 1.5% 1.25 98.7 % 
  3 0.9999 1.47 0.05 3.3% 1.25 117.9 % 
MDA 1 0.9999 1.02 0.04 3.6% 1.30 78.7 % 
  2 1.0000 1.25 0.04 2.9% 1.30 96.3 % 
  3 1.0000 1.28 0.04 3.2% 1.30 98.3 % 
Codeine 1 0.9999 0.99 0.12 12.3% 1.06 93.5 % 
  2 1.0000 1.09 0.04 3.4% 1.06 102.6 % 
  3 1.0000 1.11 0.03 3.1% 1.06 104.5 % 
Morphine 1 1.0000 1.30 0.08 6.5% 1.44 90.3 % 
  2 1.0000 1.38 0.03 2.3% 1.44 95.6 % 
  3 1.0000 1.38 0.03 2.4% 1.44 95.7 % 
6-MAM 1 0.9999 1.41 0.12 8.6% 1.33 106.0 % 
  2 0.9999 1.54 0.08 4.9% 1.33 115.5 % 
  3 0.9998 1.64 0.12 7.4% 1.33 123.3 % 
 
Table 3-12: Detection of Drugs in Hair Inter-day Validation Results Summary 
Hair Validation Inter-day Summary 
        
  Mean Std Dev CV Actual Conc. Accuracy 
MDMA 1.33 0.12 8.7% 1.25 106.7 % 
Amphetamine 0.91 0.08 9.3% 1.15 79.4 % 
Methamphetamine 1.25 0.10 8.2% 1.17 106.4 % 
BZP 1.35 0.11 8.3% 1.25 108.2 % 
MDA 1.18 0.12 10.5% 1.3 91.1 % 
Codeine 1.06 0.09 8.3% 1.06 100.2 % 
Morphine 1.35 0.06 4.7% 1.44 93.8 % 
6-MAM 1.53 0.14 9.1% 1.33 114.9 % 
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LOD were all very low and fitted within concentrations found in casual to 
abuser drug users hair. This is shown in Table 3-14. 
 
Table 3-13: LOD and Common Drug Levels Found in Hair of Casual Users/Abusers 
 
 
 
Approximate LOD 
(ng/mg) 
Common Levels Found 
in Casual Users - 
Abusers (ng/mg) 
References 
Methamphetamine 0.02 0.30 - 22.7 ng/mg  64, 94 
MDMA 0.001 0.56 - 64.42 ng/mg  64, 95 
MDA 0.04 0.05 - 1.06 ng/mg  64, 95 
BZP 0.03 Unknown   
Amphetamine 0.06 0.1 - 4.8 ng/mg  94, 95  
Morphine 0.01 0.1 (cut off) - 54 ng/mg  64, 9 
Codeine 0.08 0.52 - 1.89 ng/mg  64 
6-MAM 0.01 0.1 (cut off) - 65 ng/mg  64, 9 
 
 
The potential of phentermine to interfere with the quantitation of 
methamphetamine was assessed by spiking known concentrations of 
phentermine into two standards during a validation run. Phentermine has the 
same mass as methamphetamine and a similar retention time, however the 
main transition of phentermine (150.1/133) differs from that of 
methamphetamine (150.1/91.1). Figure 3-16 shows the distinctive peak of 
phentermine next to methamphetamine in a spiked sample, monitoring the 
transition of 150/91 shared by both drugs. To correctly identify 
methamphetamine, the ratios of the transition ions need to stay constant. If 
phentermine is present it can be identified by monitoring the transition 
150/133. 
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Figure 3-16: Methamphetamine Peak LC-MS/MS Showing Phentermine Interference at 
0.5 ng/mg 
 
 
 
3.2.4. Samples 
 
Three samples previously analysed for methamphetamine and amphetamine 
by GC-MS were analysed using the above method. The results can be seen in 
Table 3-14. LC-MS/MS results for two samples, previously reported to 
contain methamphetamine, were similar to the GC-MS concentrations. Sample 
2 also showed a low level of MDMA (which was not detected in the GC-MS 
method). The results for the third sample also agreed with previous results 
with no drugs detected. The washings of each hair sample were retained and 
were negative for all drugs. 
 
Table 3-14: Results of Actual Hair Samples Analysed by LC-MS/MS 
Sample Drug/s Detected Concentration 
Concentration of 
Methamphetamine 
Measured by GC-
MS (LOD 0.5 ng/mg) 
1 (845) Methamphetamine 0.0913 ng/mg 0.06 ng/mg 
2 (159) Methamphetamine 
MDMA 
0.169 ng/mg 
0.130 ng/mg 
0.15, 0.13 ng/mg 
Not Detected 
3 (665E) None N/A No Drugs Detected 
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Chapter 4: Discussion/Conclusion 
 
4.1. Discussion Of Results 
 
4.1.1. The effects on driving performance of the legal party drugs BZP 
and TFMPP alone and in combination with alcohol 
 
Suppliers state on packaging and websites, that users should take one dose 
(this could be 1-2 tablets/capsules) then take another dose 1-2 hours later if 
required. However the time taken for BZP and TFMPP to absorb into the 
bloodstream appears to be a lot longer than expected. From the results it is 
evident that the drugs are not completely absorbed until approximately 4-5 
hours after the initial dose, which is 2-3 hours after the final dose. This could 
explain why users are being admitted to hospital emergency wards, as it would 
be easy for a user to take too many pills under the assumption that they are not 
working. 
 
During the testing of tablets and capsules for uniformity (see Appendix A) a 
few different kinds of over-the-counter party pills were tested. It appeared that 
the package labelling could be misleading and hard to follow. The ingredients 
on the package were listed per serving size, which differed between 
formulations (e.g. for Jet and Bliss this was two capsules and for E-Formula it 
was one tablet). Without reading the package cautiously it could be hard for 
the user to establish what dose of BZP or TFMPP they would be receiving. 
Results from the prevalence study in Hamilton showed that only 64 % of users 
read the packet specifications before using the pills and 32.8 % self-reported 
that they had taken more than the recommended amount.47 It would appear 
that this could also contribute to the small percentage of users that have ended 
up in the emergency wards at hospitals around New Zealand.  
 
There is nothing in the literature that suggests a safe dosage level for BZP and 
TFMPP, however manufacturers recommendations and package labelling 
suggest the recommended dose of BZP containing party pills is somewhere 
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around 200-300 mg, a safe level for TFMPP has not been mentioned. The 
amount given to the subjects in this study, models the higher end of the 
recommended dose sold at retail outlets and specified on the packaging. The 
autopsy case in Sweden found a level of 1.78 µg/mL,29 which is over twice the 
highest levels seen here. This level, however, was said only to have 
contributed to the case and the significance of the contribution is unknown. 
 
According to the house-hold survey carried out by SHORE,48 15.9 % of those 
who took legal party pills, self-reported they completed at least some of their 
driving under the influence of the pills. The effect of stimulants on driving has 
not been conclusively determined. Methamphetamine has been shown to 
improve alertness, and psychomotor abilities, however epidemiological 
studies indicate that it may cause impairment in drivers.96 Amphetamine has 
been shown to improve driving performance in small doses,97,98 although the 
effects of large quantities (taken by drug abusers) has not been assesed.96 
There have been no driving performance studies conducted on MDMA, 
however it has been shown to impair cognitive abilities in users,96 so may 
have negative effects on driving. BZP has very close similarities to 
amphetamine, therefore it is not entirely surprising that BZP enhanced driving 
performance. However it is often at the end of the night that users will be 
driving, and they are often “coming down” off the drugs, possibly having been 
awake for several hours. In this situation users can suffer from fatigue, which 
is a well-known cause of fatal road crashes. Some of the volunteers 
experienced fatigue and exhaustion after administration of BZP and TFMPP, 
this could be a potential risk associated with taking the party pills and driving. 
 
A preliminary estimation of half-life can be calculated using two points (t1 = 
6.5 hours and t2 = 10 hours) by the following formulae: 
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Where:  t1  = Point obtained after drug has been fully distributed 
 t2  = Point obtained at some time later than t1 
  
 
Calculated for each individual who received party pills, the average half-life 
for BZP was 8 hours, compared with 6 hours for TFMPP. The highest and 
lowest points are shown in Table 4-1. This excludes one individual for BZP as 
there was no significant change from 6.5 to 10 hours. 
 
Table 4-1: Estimated Half-life of BZP and TFMPP 
 T1/2 (hours) BZP T1/2 (hours) TFMPP 
Maximum 20 12 
Minimum 4 3 
Average 8 6 
Standard Deviation 4 3 
 
Any calculation of half-lives from two points (6.5 and 10 hours) is unreliable 
however, the concentrations and estimated half-life, give a good indication of 
concentration and time range for planning a rigorous pharmacokinetics study. 
 
The study was stopped halfway through due to adverse reactions to the pills 
suffered by 41 % of those who where given the party pills (compared to no 
adverse effects observed in the placebo group). The effects observed were 
similar to those seen in the emergency ward at Christchurch Hospital.25 It can 
be concluded that these pills, when taken in dosages as suggested by 
manufacturers, can still cause severe adverse reactions and marked 
cardiovascular effects.  
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The findings from this study have been reported by MRINZ to the EACD who 
in turn has made a recommendation to the government based on these 
findings, and results from other groups undertaking study on BZP in New 
Zealand. The EACD has recommended that the BZP pills should be made 
illegal and suggested they be placed in a similar class to cannabis (Class C, 
Misuse of Drugs Act). Communities in New Zealand have varying opinions 
however on the future status of these drugs. As the drugs are marketed for 
harm minimisation, it is possible that users of the drugs may turn to harder 
drugs such as methamphetamine, if the party drugs are made illegal. Making 
the drugs illegal could push them underground, possibly falling into a similar 
position to methamphetamine or MDMA. The harms of combining drugs are 
unknown, and a mixture of BZP and, for example, MDMA could be 
potentially dangerous, or lethal. By placing tighter restrictions on the drugs, 
and providing education to the public, they would fall into a category similar 
to that of alcohol. Research shows that the pills have some adverse reactions 
in users. Although there have been no known deaths attributed to the sole use 
of BZP and TFMPP containing party pills, safe dose and lethal dose levels are 
still unknown. By making the pills illegal, theoretically less of the population 
will be exposed to them, thereby reducing associated risks. 
 
The LC-MS/MS method for the detection of BZP and TFMPP in blood, has 
great linearity over a wide range (10-10,000 ng/mL), with CVs under 10 %, 
and accuracy greater than 90 % at low concentrations (BZP 17.7 and 53.3 
ng/mL, TFMPP 7.2 and 28.3 ng/mL) therefore falling within requirements 
suggested by validation guidelines. The method is quick, with limited 
preparation required by the analyst, especially using automated SPE. Also 
time consuming evaporation of samples after SPE, was eliminated by eluting 
samples off the column in pure acetonitrile, requiring only a dilution, before 
LC-MS/MS. 
 
The method could be improved by monitoring a second transition of BZP and 
TFMPP. However as we were only looking for known drugs for this study, it 
was not crucial to have more than one transition. In the case of forensic testing 
however, it would be necessary, as the monitoring of two (or more) transition 
- 79 - 
ions would ensure absolute certainty of the identity of the drug. Specificity of 
identification is essential to forensic cases, as often the fate of an individual 
relies on the final result given by a forensic scientist. Forensic methods are 
subjected to scrutiny so there needs to be a high level of reliability, and 
extensive quality assurance and quality control programs in place.99 LC-MS is 
currently the standard for a lot of forensic analysis and this project is a good 
example of how reliable it can be and the potential applications it has for the 
future.  
 
4.1.1. Detection of Multiple Recreational Drugs in Hair by  
LC-MS/MS 
 
The aim of the project was to detect and quantify levels of different 
recreational drugs in hair. The method was successful in detecting 
methamphetamine, amphetamine, MDMA, MDA, BZP, morphine, codeine 
and 6-MAM. All CVs were below 12 % and the accuracies were acceptable 
for all drugs. 
 
The method proved useful for analysing drugs in hair. The accuracy of the 
method is not optimum for amphetamine, but the need for accurate 
quantitation is not an essential requirement. The method also gave valid 
identification for all drugs, which is fundamental in any forensic method. It 
monitored three transitions for each drug, giving consistent ratios of the first 
transition ion to the second and third transtions. 
 
The validation for this method was carried out with blank hair samples, spiked 
with drugs. This does not quite represent a true hair sample, as the drugs are 
not incorporated within the hair, like that of a drug user. By testing three 
samples from previous cases, the reliability of the method was further tested. 
The results proved very successful with agreement between the developed 
method and the previously used GC-MS method. It also showed great 
specificity, as there was no interference seen in the samples. This is especially 
important in hair samples as due to the complexitiy of the matrix, interference 
can be a problem. 
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The ability of the method to detect multiple drugs saves time and reduces 
costs. By using an automated SPE method for sample clean-up, the time the 
analyst spends preparing the samples is also reduced. 
 
The SPE method had good extraction efficiencies for all drugs except 6-
MAM. Table 3-14 shows the approximate detection limit for 6-MAM 
calculated at 0.01 ng/mg. The concentration ranges detected for 6-MAM in 
drug users and abusers were well within this limit, so even though a large loss 
is occurring, 6-MAM would still be detected by the LC-MS/MS. The 
possibility of hydrolysis of 6-MAM to morphine during the extraction in acid 
overnight could explain a lower recovery and is mentioned in other 
articles.64,92 For future development of this method, trying different SPE 
cartridges and changing the elution solvent (perhaps using a different solvent 
or doing more elutions) may improve recoveries for 6-MAM and the other 
drugs. 
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4.2. Conclusion 
 
There still remains a lot of research to be done on BZP and TFMPP (as with 
many other drugs of abuse). Depending on the legal status of the drug and the 
ability of scientists to carry out research, many different aspects of the drug 
could be investigated. Testing of the drug in hair and nails could prove 
valuable in forensic cases as well as the testing of oral fluid for roadside drug 
analysis. More knowledge on its mechanisms of action and pharmacokinetics 
would also prove beneficial. 
 
The LC-MS/MS method developed for this study proved reproducible, reliable 
and accurate, specific and was easily adapted to test for other drugs of abuse. 
The method could be modified to include other legal recreational piperazines 
such as MeOPP, mCPP, Flipiperazine (p-fluorophenylpiperazine, PFPP) 
which are also beginning to appear on the market in New Zealand. 
 
Solid phase extraction was an important part of both methods, and provided a 
fast automated clean-up of both blood and hair samples. For further work in 
this area, the extraction efficiency of the different columns (Strata X and 
Certify Bond Elut) could be determined. It may even be possible to develop 
one SPE method which can be used for multiple biological matrices. 
 
The overall findings of the BZP and TFMPP safety study show that the dosage 
(300 mg BZP.2HCl and 72 mg TFMPP.2HCl taken in two doses at two hourly 
intervals), which represents the recommended intake (as stated by 
manufacturers) can cause serious adverse reactions in humans. BZP has very 
close similarities to amphetamine, as demonstrated by its stimulant properties 
in this report and supported by other studies.31,33,34,39,44 It is also said to have a 
similar abuse liability to amphetamine,31 however the undesirable side effects 
have also been said to deter users. The legal status of these piperazines 
remains in question, and their future lies in the hands of the government. 
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The method for the testing of multiple drugs in hair proved fairly simple, 
quick, and robust. It achieved lower limits of detection (0.02 ng/mg 
methamphetamine) than GC-MS (0.05 ng/mg methamphetamine) and similar 
results to samples previously reported. 
 
Overall, the LC-MS/MS method using a strong cation exchange column 
proved very versatile with all drugs measured, and could probably be easily 
adapted to accommodate other, or new similar designer drugs of abuse in 
different biological matrices. 
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Appendix A: Tablet Uniformity 
 
 
A.1 Method for Quantitation of Tablets 
 
It is important that the capsules that the volunteers received contained (within 
analytical variation) the same amount of BZP and TFMPP. Three different 
types of party pill obtained over-the-counter from Cosmic Corner (E-Formula, 
Jet, Bliss) were analysed. Ten of each tablet/capsule were diluted 1000-fold 
(in 50 mL ethanol (to dissolve) and deionised water), 50 µL of internal 
standard was added, then the tablets were analysed by LC-MS-MS using the 
method described in section 2.1.3. The results were compared to the normal 
extracted curve, and concentrations of the drugs were determined. Following 
this, ten capsules formulated by the hospital pharmacy (combination of Jet and 
Bliss) for MRINZ were analysed in the same manner as above. 
 
A.2 Results for Tablet Uniformity 
 
Three types of over-the-counter tablets/capsules (ten of each brand) were 
analysed. As the labelling did not indicate what form of BZP/TFMPP the 
capsules contained, this had to be worked out by comparing the amount 
indicated with the actual amount found. It was concluded that the amount 
contained in the pills was in the form of the dihydrochloride salt (BZP.2HCl). 
A summary of this can be seen in Table A-1. 
 
The party pills bought from Cosmic Corner contained varying amounts of the 
drugs, as demonstrated by the high standard deviation (S.D). The final 
capsules (the ones administered) were formulated by homogeneously 
combining two types of capsules (bought over the counter) into new capsules 
(this was done by the hospital pharmacy, and sent to ESR for analysis).  The 
final formulation contained 75 mg of BZP.2HCl and 18 mg of TFMPP.2HCl 
and varied only within analytical measures.  
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Table A-1: Capsule Analysis of Over-the-Counter Party Pills  
(adapted from reference 93) 
Brand BZP.2HCl (mg) TFMPP.2HCl (mg) 
 
Amount as 
indicated on 
packaging 
(S.D) 
Amount as 
found by 
analysis 
(S.D) 
Amount as 
indicated on 
packaging  
(S.D) 
Amount as 
found by 
analysis  
(S.D) 
E-Formula 160 Both 129 (4.4) 160 Both 39 (1.7) 
Jet 85 91 (5.8) 10 10 (0.8) 
Bliss 50 55 (4.8) 25 25 (2.5) 
Pharmacy 
Capsules N/A 75 (2.2) N/A 18 (0.7) 
 
 
The capsules also contain (as stated on packaging); L-glutamine, D,L-
phenylalanine, L-tyrosine, Ginko biloba extract, ginger extract, Guarana 
extract, antioxidants, minerals, vitamin B complex and vitamin C. However 
analysis for quantities/presence of these ingredients was not carried out. These 
ingredients are commonly found in most formulations sold at various retail 
outlets. 
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Appendix B : Fragmentation Patterns 
 
Figure B-1: Proposed Fragmentation of BZP 
 
Figure B-2: Proposed Fragmentation of TFMPP 
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Figure B-3: Proposed Fragmentation of Methamphetamine 
 
 
Figure B-4: Proposed Fragmentation of Amphetamine 
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Figure B-5: Proposed Fragmentation of MDMA 
 
 
 
Figure B-6: Proposed Fragmentation of MDA 
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Figure B-7: Proposed Fragmentation of Morphine (adapted from reference 100) 
 
Figure B-8: Proposed Fragmentation of Codeine (adapted from reference 100) 
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Figure B-9: Proposed Fragmentation of 6-MAM (adapted from reference 100) 
 
+ 
m/z 165 CH3OCO 
+ O 
HO 
+ O 
m/z 193 m/z 211 
+ 
H 
CH3 
m/z 328 
- 90 - 
Appendix C: Validation Results 
 
Table C-1: BZP/TFMPP Validation Data 
Range: BZP 7-7000 ng/mL Calibration Curve: BZP 0.002
TFMPP 10-10000 ng/mL TFMPP 0.01
Correlation Coeff: BZP 0.999
TFMPP 0.999
Intra-day Results
BZP (17.7 ng/mL) 14/06/2006 BZP (17.7 ng/mL) 19/06/2006
22.203 22.537
21.154 18.623
20.889 19.346
20.021 19.264
19.023 17.587
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
20.7 1.2 5.8% 116.7% 19.5 1.9 9.5% 110.0%
BZP (17.7 ng/mL) 22/06/2006
20.483
18.961
21.783
18.730
18.819
Mean Std Dev CV Accuracy
19.8 1.3 6.8% 111.6%
TFMPP (28.3 ng/mL) 14/06/2006 TFMPP (28.3 ng/mL) 19/06/2006
31.154 33.749
25.615 32.588
27.952 30.690
27.019 30.249
26.946 26.791
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
27.7 2.1 7.5% 98.0% 30.8 2.7 8.6% 108.9%
TFMPP (28.3 ng/mL) 22/06/2006
29.170
28.347
28.798
23.136
27.209
Mean Std Dev CV Accuracy
27.3 2.5 9.0% 96.6%
Inter-day Results
BZP TFMPP
22.203 22.537 20.483 31.154 33.749 29.170
21.154 18.623 18.961 25.615 32.588 28.347
20.889 19.346 21.783 27.952 30.690 28.798
20.021 19.264 18.730 27.019 30.249 23.136
19.023 17.587 18.819 26.946 26.791 27.209
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
20.0 1.5 7.40% 112.8% 28.6 2.8 9.6% 101.2%
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Table C-2: BZP/TFMPP Validation Data 
Range: BZP 30-1495 ng/mL Cal. Curve: BZP 0.006
TFMPP 4-207 ng/mL TFMPP 0.044
Correlation Coeff: BZP 0.999
TFMPP 0.999
Intra-day Results
BZP (52.3 ng/mL) 19/07/2006 BZP (52.3 ng/mL) 1/09/2006
52.112 59.241
51.178 59.548
53.625 58.493
50.312 58.190
51.864 58.050
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
51.8 1.2 2.4% 99.1% 58.7 0.7 1.1% 112.2%
BZP (52.3 ng/mL) 12/09/2006
56.422
53.424
52.355
51.955
53.951
Mean Std Dev CV Accuracy
53.6 1.8 3.3% 102.5%
TFMPP (7.2 ng/mL) 19/07/2006 TFMPP (7.2 ng/mL) 1/09/2006
7.645 7.141
6.440 6.550
7.309 6.296
7.646 7.135
6.680 6.874
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
7.1 0.6 7.8% 99.2% 6.8 0.4 5.5% 94.4%
TFMPP (7.2 ng/mL) 12/09/2006
7.565
6.331
5.998
6.319
6.272
Mean Std Dev CV Accuracy
6.5 0.6 9.4% 90.2%
Inter-day Results
BZP TFMPP
52.112 59.241 56.422 7.645 7.141 7.565
51.178 59.548 53.424 6.440 6.550 6.331
53.625 58.493 52.355 7.309 6.296 5.998
50.312 58.190 51.955 7.646 7.135 6.319
51.864 58.050 53.951 6.680 6.874 6.272
Mean Std Dev CV Accuracy Mean Std Dev CV Accuracy
54.7 3.2 5.9% 104.6% 6.8 0.6 8.2% 94.6%
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Appendix D: MS Parameters for Hair Analysis 
 
Table D-1: Collision Cell Parameters for Various Drugs Tested In Hair. 
Drug M+ Fragment Ion DP (V) CEP (V) CE (V) 
91.1 34.0 4.65 54.0 
119.30 34.0 4.65 23.00 Methamphetamine 150.1 
65.2 34.0 4.65 56.0 
91.09 26.0 4.25 49.0 
119.1 26.0 4.25 21.0 Amphetamine 136.06 
65.07 26.0 4.25 51.0 
163 38.0 5.93 28.0 
135.1 38.0 5.93 43.0 MDMA 194.10 
105.10 38.0 5.93 43.0 
163.2 28.0 5.53 25.0 
133.0 28.0 5.53 28.0 MDA 180.05 
105.1 28.0 5.53 36.0 
91.10 41.0 5.44 63.0 
85.20 41.0 5.44 22.0 BZP 177.12 
65.10 41.0 5.44 62.0 
152.1 45.0 8.60 76.0 
165.2 45.0 8.60 52.0 Morphine 286.12 
183.2 45.0 8.60 37.0 
165.18 61.0 9.01 51.0 
152.16 45.0 9.01 81.0 Codeine 303.20 
128.16 45.0 9.01 73.0 
165.11 73.0 9.82 65.0 
211.11 73.0 9.82 34.0 6-MAM 328.12 
193.10 73.0 9.82 37.0 
NB: DP – declustering potential, CE – collision energy, CEP – collision entrance 
potential. 
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Appendix E : LC-MS/MS Raw Data (BZP and TFMPP in Blood) 
 
Figure E-1: LC-MS/MS S6 Standard ( BZP 177 ng/mL; TFMPP 283 ng/mL) 
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Figure E-2: LC-MS/MS Sample 1634/35 - 0 Hours (Contains no BZP or TFMPP, but shows 
BZP.d7 and TFMPP.d4 Internal Standards) 
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Figure E-3: LC-MS/MS Sample 1634/37 - 3.5 Hours (BZP 433 ng/mL; TFMPP 28 ng/mL) 
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Figure E-4: LC-MS/MS Sample 1634/36 - 6.5 Hours (BZP 464 ng/mL; TFMPP 26 ng/mL) 
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Figure E-5: LC-MS/MS Sample 1634/38 - 10 Hours (BZP 338 ng/mL; TFMPP 18 ng/mL) 
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